Cryomass (CRYM) S-1 17 Jun 22 IPO registration Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Mar. 31, 2022
Document Information Line Items
Entity Registrant Name	Cryomass Technologies, Inc.
Document Type	S-1
Amendment Flag	false
Entity Central Index Key	0001533030
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 3,594,275	$ 5,772,839	$ 329,839
Accounts receivable, net			540,000
Prepaid expenses	73,178	757,383	60,475
Assets held for sale, current			6,867,840
Total current assets	3,667,453	6,530,222	7,798,154
Loan receivable	4,218,831	3,600,000
Property and equipment, net	233,641	225,000
Goodwill	1,190,000	1,190,000
Intangible assets, net	4,016,768	4,038,600
Total assets	13,326,693	15,583,822	7,798,154
Current liabilities:
Accounts payable and accrued expenses	1,364,905	1,881,648	2,248,235
Loans payable			412,560
Taxes payable		771	771
Liabilities held for sale, current			1,464,285
Total current liabilities	1,364,905	1,882,419	4,125,851
Notes payable	208,333	177,083	52,083
Deferred tax liability			14,926
Total liabilities	1,573,238	2,059,502	4,192,860
Commitments and contingencies (Note 15)
Preferred stock
Common stock	199,144	196,950	97,006
Additional paid-in capital	42,215,245	41,916,207	19,138,947
Common stock to be issued	80,208		98,535
Accumulated deficit	(30,741,142)	(28,588,837)	(15,729,194)
Total shareholders’ equity	11,753,455	13,524,320	3,605,294
Total liabilities and shareholders’ equity	$ 13,326,693	15,583,822	$ 7,798,154
Previously Reported [Member]
ASSETS
Cash and cash equivalents		5,772,839
Prepaid expenses		757,383
Total current assets		6,530,222
Loan receivable		3,600,000
Property and equipment, net		225,000
Goodwill		1,190,000
Intangible assets, net		4,038,600
Total assets		15,583,822
Current liabilities:
Accounts payable and accrued expenses		1,882,419
Total current liabilities		1,882,419
Notes payable		177,083
Total liabilities		2,059,052
Preferred stock
Common stock		196,950
Additional paid-in capital		41,916,207
Accumulated deficit		(28,588,837)
Total shareholders’ equity		13,524,320
Total liabilities and shareholders’ equity		$ 15,583,822

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000	100,000	100,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	199,143,664	196,949,801	97,005,817
Common stock, shares outstanding	199,143,664	196,949,801	97,005,817
Previously Reported [Member]
Preferred stock, par value (in Dollars per share)		$ 0.001
Preferred stock, shares authorized		100,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)		$ 0.001
Common stock, shares authorized		500,000,000
Common stock, shares issued		196,949,801
Common stock, shares outstanding		196,949,801

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales				$ 781,455
Cost of goods sold				744,279
Operating expenses:
Amortization expense	21,832
Net loss per common share:
Gross profit				37,176
Personnel costs	335,230	373,714	3,207,110	2,473,730
Sales and marketing			44,095	14,854
General and administrative	295,349	396,470	3,939,131	2,338,599
Legal and professional fees	1,458,257	225,520	757,828	1,744,834
Research and development	17,122		43,663
Total operating expenses	2,127,790	995,704	7,991,827	6,572,017
Loss from operations	(2,127,790)	(995,704)	(7,991,827)	(6,534,841)
Interest expense - net	(36,023)	(202,609)	(2,189,959)	(236,912)
Gain on foreign exchange	11,508	34,770	47,144	(88,690)
Total other expenses	(24,515)	(167,839)	(2,142,815)	(325,602)
Net loss from continuing operations, before taxes	(2,152,305)	(1,163,543)	(10,134,642)	(6,860,443)
Income taxes
Net loss from continuing operations	(2,152,305)	(1,163,543)	(10,134,642)	(6,860,443)
Net gain from discontinued operations, net of tax		116,616	(2,725,001)	(4,955,464)
Net loss	(2,152,305)	(1,046,927)	(12,859,643)	(11,815,907)
Comprehensive loss from discontinued operations
Comprehensive loss	$ (2,152,305)	$ (1,046,927)	$ (12,859,643)	$ (11,815,907)
Loss from continuing operations - basic and diluted (in Dollars per share)	$ (0.01)	$ (0.01)	$ (0.06)	$ (0.07)
Gain / (loss) from discontinued operations - basic and diluted (in Dollars per share)			(0.02)	(0.05)
Loss per common share - basic and diluted (in Dollars per share)	$ (0.01)	$ (0.01)	$ (0.08)	$ (0.12)
Weighted average common shares outstanding—basic and diluted (in Shares)	198,268,853	98,257,687	157,509,715	99,863,059

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Provision for inventory loss	$ 0	$ 400,787
Loss on disposal	$ 3,021,724	$ 3,021,724

Consolidated Statements of Shar

Consolidated Statements of Shareholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Common Stock to Be Issued	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 106,216	$ 16,894,103		$ (3,913,287)	$ 13,087,032
Balance (in Shares) at Dec. 31, 2019	106,216,708
Issuance of common stock pursuant to separation agreement	$ 1,176	148,824			150,000
Issuance of common stock pursuant to separation agreement (in Shares)	1,175,549
Issuance of common stock pursuant to accelerated vesting of RSU’s	$ 600	162,440			163,040
Issuance of common stock pursuant to accelerated vesting of RSU’s (in Shares)	600,000
Stock-based compensation - shares	$ 758	570,954			$ 571,712
Stock-based compensation - shares (in Shares)	757,895				99,863,059
Stock-based compensation - options		555,532			$ 555,532
Share cancellations	$ (15,350)	15,350
Share cancellations (in Shares)	(15,350,000)
Share issuance from sale of common stock	$ 3,606	541,744			545,350
Share issuance from sale of common stock (in Shares)	3,605,665
Common stock to be issued			98,535		98,535
Beneficial Conversion Feature of Note Payable		250,000			250,000
Net loss				(11,815,907)	(11,815,907)
Balance at Dec. 31, 2020	$ 97,006	19,138,947	98,535	(15,729,194)	$ 3,605,294
Balance (in Shares) at Dec. 31, 2020	97,005,817
Stock-based compensation - shares (in Shares)					98,257,687
Share issuance from sale of common stock	$ 1,492	207,043	(98,535)		$ 110,000
Share issuance from sale of common stock (in Shares)	1,491,819
Stock-based compensation		250,817			250,817
Net loss				(1,046,927)	(1,046,927)
Balance at Mar. 31, 2021	$ 98,498	19,596,807		(16,776,121)	2,919,184
Balance (in Shares) at Mar. 31, 2021	98,497,636
Balance at Dec. 31, 2020	$ 97,006	19,138,947	98,535	(15,729,194)	3,605,294
Balance (in Shares) at Dec. 31, 2020	97,005,817
Stock-based compensation - shares		784,364			$ 784,364
Stock-based compensation - shares (in Shares)					157,509,715
Stock-based compensation - options		968,205			$ 968,205
Share issuance from sale of common stock	$ 53,192	9,556,368	(98,535)		9,511,025
Share issuance from sale of common stock (in Shares)	53,191,819
Share issuance related to CryoCann asset purchase	$ 10,000	1,794,500			1,804,500
Share issuance related to CryoCann asset purchase (in Shares)	10,000,000
Share issuance pursuant to employment agreements	$ 6,702	894,000			900,702
Share issuance pursuant to employment agreements (in Shares)	6,701,586
Share issuance in exchange for extinguishment of debt	$ 27,095	5,381,308			5,408,403
Share issuance in exchange for extinguishment of debt (in Shares)	27,121,119
Share issuance in exchange for services	$ 2,837	965,175			968,012
Share issuance in exchange for services (in Shares)	2,837,333
Share issuance for interest on note payable	$ 118	49,823			49,941
Share issuance for interest on note payable (in Shares)	92,127
Beneficial Conversion Feature of Note Payable		515,763			515,763
Fair value of warrants issued		1,867,754			1,867,754
Net loss				(12,859,643)	(12,859,643)
Balance at Dec. 31, 2021	$ 196,950	41,916,207		(28,588,837)	$ 13,524,320
Balance (in Shares) at Dec. 31, 2021	196,949,801
Stock-based compensation - shares (in Shares)					198,268,853
Stock-based compensation	$ 1,736	139,079			$ 140,815
Stock-based compensation (in Shares)	1,735,529
Share issuance in exchange for services	$ 458	159,959	80,208		240,625
Share issuance in exchange for services (in Shares)	458,334
Net loss				(2,152,305)	(2,152,305)
Balance at Mar. 31, 2022	$ 199,144	$ 42,215,245	$ 80,208	$ (30,741,142)	$ 11,753,455
Balance (in Shares) at Mar. 31, 2022	199,143,664

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,152,305)	$ (1,163,543)	$ (10,134,642)	$ (6,860,443)
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations:
Amortization of debt discount	31,250	31,250	1,547,181	52,083
Depreciation and amortization expense	21,832		43,663
Bad debt expense			540,000
Fair value of common stock issued pursuant to service and advisory agreements	160,417		1,011,075	7,500
Payable extinguishment for services not provided			318,970
Provision for inventory loss				400,787
Stock-based compensation expense	140,815	250,817	2,653,271	1,440,284
Deferred income tax expense			(14,926)	10,235
Change in operating assets and liabilities:
Accounts receivable				(540,000)
Prepaid expenses	684,205	30,238	(696,908)	40,080
Inventory, net				(60,787)
Accounts payable and accrued expenses	(517,514)	190,848	(366,587)	1,493,385
Taxes payable				771
Net cash used in operating activities from continuing operations	(1,631,300)	(660,390)	(5,098,903)	(4,016,105)
Net cash provided by / (used in) operating activities from disc ops		194,167	(501,609)	266,484
Net cash used in operating activities	(1,631,300)	(466,223)	(5,600,512)	(3,749,621)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash Payment for CryoCann asset purchase			(1,000,000)
Payoff of CryoCann loan agreement at closing			(1,247,684)
Issuance of loans receivable	(618,831)
Purchase of property and equipment	(8,641)		(225,000)
Net cash used in investing activities from continuing operations	(627,472)		(2,472,684)
Net cash used in investing activities from discontinued operations		(174,003)	(330,560)	(693,255)
Net cash used in investing activities	(627,472)	(174,003)	(2,803,244)	(693,255)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable, related parties			237,590
Repayment of notes payable, related parties			(237,590)
Proceeds from issuance of common stock		110,000	10,308,000	537,850
Proceeds from common stock subscribed and to be issued	80,208			98,535
Proceeds from loans payable, net of repayment		136,778
Proceeds from loans payable, current			286,441
Repayment of loans payable, current			(698,800)	412,560
Proceeds from notes payable		725,000	4,900,000	250,000
Repayment of seller note for acquisition			(1,173,016)
Related party note disbursement			(281,771)
Net cash provided by financing activities from continuing operations	80,208	971,778	13,340,854	1,298,945
Net cash provided by financing activities from discontinued operations			505,902
Net cash provided by financing activities	80,208	971,778	13,846,756	1,298,945
Net increase / (decrease) in cash from continuing operations	(2,178,564)	311,388	5,769,267	(2,727,395)
Net increase / (decrease) in cash from discontinued operations		20,164	(326,267)	(426,771)
Cash at beginning of period	5,772,839	329,839	329,839	3,473,770
Cash at end of period	3,594,275	661,391	5,772,839	329,839
Supplemental disclosure of cash flow information:
Cash paid for interest		125,065	449,068	162,810
Supplemental disclosure of non-cash investing and financing activities:
Common stock issued pursuant to separation agreement				150,000
Common stock issued pursuant to vesting of restricted stock units	$ 848,500	$ 146,602	2,851,103	163,040
Loan receivable issued pursuant to disposal of discontinued operations			$ 3,600,000

Nature of the Business

Nature of the Business	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Cryomass Technologies Inc (“Cryomass Technologies” or the “Company”) owns and is developing the strategy to operate patented cryo-mechanical technology is for the separation of plant materials in the harvesting of hemp and cannabis, and potentially other high value crops such as hops. The system exploits CryoMass’s U.S.-patented process for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The device currently under development is scaled for highway transportability and is being optimized for the low-cost collection of fully intact hemp and cannabis trichomes. The functional “beta” machine is expected to be fully field-tested during mid-2022, followed by commercial use of the equipment including revenue generation.	1. NATURE OF THE BUSINESS Cryomass Technologies Inc (“Cryomass Technologies” or the “Company”) began as Auto Tool Technologies Inc., which was incorporated under the laws of the State of Nevada on May 10, 2011. The Company’s name was changed to AFC Building Technologies Inc. effective January 10, 2014. Effective April 26, 2018, the Company changed its name to First Colombia Development Corp. Effective October 14, 2019, the Company changed its name to Redwood Green Corp. Effective September 1, 2020, the Company changed its name to Andina Gold Corp. On July 15, 2021, the Company entered into a plan of merger with its wholly-owned subsidiary, Cryomass Technologies Inc a Nevada corporation, pursuant to which we agreed that subsidiary would merge with and into our company. Following the consummation of the merger, the separate existence of the subsidiary ceased, and we continued as the surviving corporation with our name changed to Cryomass Technologies Inc. effective August 27, 2021. Our ticker symbol changed from AGOL to CRYM. The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this prospectus. The Company over its history has explored a number of different business opportunities. On May 10, 2018, the Company acquired all the issued and outstanding share capital of First Colombia Devco S.A.S. (“Devco”) a Colombian company and began to establish various business ventures in Colombia in the agriculture and real estate development, tourism, and infrastructure sectors before commencing to phase them out in April 2019. On July 1, 2019, the Company acquired 100% of the membership interests in General Extract, LLC (“General Extract”), a Colorado limited liability company. General Extract was founded in 2015 as an importer, distributor, broker and postprocessor of hemp and hemp derivatives. The Company acquired all of the issued and outstanding membership interests, including business plans and access to contacts. Effective August 27, 2021, General Extract became Cryomass LLC. On July 15, 2019, the Company, through its wholly owned subsidiary Good Acquisition Co., entered into a Membership Interest Purchase Agreement to acquire cannabis-related intellectual property and other assets of Critical Mass Industries LLC DBA Good Meds (“CMI” and/or “Good Meds”), a Colorado limited liability company (“CMI Transaction”). CMI is licensed by the Marijuana Enforcement Division of Colorado Department of Revenue to produce cannabis and cannabis products under its six licenses. These licenses allow for cultivation, manufacturing of infused products and retail distribution. At the time the Company entered into the Membership Interest Purchase Agreement, Colorado law prohibited public companies, including the Company, from owning cannabis licenses. Therefore, CMI spun off certain assets acquired by the Company. Under the terms of the Membership Interest Purchase Agreement, CMI retained the cannabis license, inventory and accounts receivable (the “Cannabis License Assets”) and continued to operate the cannabis business related to those assets. In consideration for the transfer of the acquired assets, the Company delivered 13,553,233 shares of the Company common stock, in addition to $1,999,770 in cash to CMI. Good Meds, the operating unit of CMI, is based in Denver, CO, and operates in a 60,000-square-foot cultivation and processing facility. This facility produces cannabis for sale as dry flower and biomass input for processing into Marijuana-Infused Products (“MIP”), such as live resin, wax and budder. Good Meds also owns and operates two medical cannabis dispensaries located in Lakewood, CO and Englewood, CO. The business has been in operation since 2009. Effective December 31, 2021, we entered into a restated and amended administrative services agreement, terminated our license and marketing agreements, and restated the asset purchase agreement with CMI and affiliates. As a result of these agreements, we disposed of all CMI-related assets and extinguished any and all related obligations. For clarity, we have no management or operations decision-making right or responsibility, nor any access to future economic benefits from operation of the assets. Therefore, upon commencing these agreements, we determined that CMI no longer qualifies as a variable interest entity as of December 31, 2021. Beginning in March 2020, an evaluation of various strategic alternatives was followed by the decision to sell the Colorado-based assets and refocus its attention on unique opportunities for gold exploration in Colombia. In August 2020, the Company established a wholly owned Colombian subsidiary, Andina Gold Colombia SAS for this purpose. In December 2020, due to the death of the top geologist exploring opportunities on behalf of the Company, and the effects of the ongoing Coronavirus pandemic, the Company determined that pursuit of gold exploration in Colombia was no longer a practical alternative. On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The aggregate purchase price was $3,500,000 million in cash and 10,000,000 shares of Company common stock As part of the Cryocann Acquisition, we retained both Cryocann employees, who have expert knowledge of the industry, related participants, customers and the acquired patented technology. Under their employment agreements, each employee may receive compensation if specific performance targets are met in association with our future operating performance when the Cryocann technology enters the market. The technology and assets acquired from Cryocann are operated from the Company’s subsidiary, Cryomass LLC. The patented cryo-mechanical technology is for the separation of plant materials in the harvesting of hemp and cannabis, and potentially other high value crops such as hops. We believe this technology will reduce processing costs and increases the quality of extracted compounds. We are exploring the application of the underlying technology to a broad range of industries that handle high-value materials and that could benefit from our precision capture methods. We anticipate that cannabis and hemp will be the first in a series of such industries. To develop and commercialize the technology, we contracted with an independent engineering and manufacturing firm to refine the design of our cryo-mechanical system for the handling of harvested hemp, cannabis and other high-value plants. The system exploits CryoMass’s U.S.-patented process for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The device currently under development is scaled for highway transportability and is being optimized for the low-cost collection of fully intact hemp and cannabis trichomes. It can be used within minutes after plants have been cut and can also efficiently capture trichomes from fresh frozen or even dried plant parts, including trim. The device’s through-put capacity is expected to be approximately 600 kilograms of gross plant material per hour. The advanced design for the equipment has been completed, and testing of a prototype machine is currently underway. The engineering and manufacturing firm has indicated that it has the capacity to build 10 to 15 such devices per month. In November we retained a second engineering and manufacturing firm to independently develop a separate machine design that applies our patented process. We expect their work to help strengthen the power and robustness of our technology. In addition, it opens a channel to a second manufacturing source. The first functional “beta” machine is expected to be ready for field testing by a third-party cannabis producer by mid-2022. The first production-run machine is expected to be ready for use towards the end of the second quarter 2022. At that moment, we expect to start helping our first tolling client (fee for service) increase its margins by cutting the cost of handling, processing and refining its hemp or cannabis and increasing the resulting material’s value to formulators of end products. Management believes the CryoMass system will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for largescale cultivators and processors of hemp and cannabis. The use of a CryoMass system – which can be trucked to and operated on the fields of most large hemp and cannabis growers or be permanently installed at a user’s processing facility – should eliminate many of the costs that come with traditional practices, especially the labor, fuel and capital costs of drying and curing hemp or cannabis that is grown for the extraction of end products. With traditional practices, harvested plants are transported to a specially constructed drying house and then treated for a week or longer under controlled conditions of temperature and humidity. It’s a costly method. With our system, harvested plants are simply fed into the front end of a CryoMass machine, and minutes later fully intact trichomes are collected at the back end of the machine. With traditional practices and their seven-to-ten days of handling and drying, a large share of a plant’s valuable trichomes break off and are lost. Then the remaining trichomes are damaged by long exposure to oxygen and by the evaporation of their volatile terpenes. The CryoMass system, on the other hand, stabilizes and collects fully intact trichomes at harvest, leaving no opportunity for such wasteful loss. Field-captured trichomes are the cleanest element of a hemp or cannabis plant because, unlike the rest of the plant, trichomes do not readily take up heavy metals, pesticides or other common soil contaminants. As a product for end-users, field-captured trichomes are closest to being contaminant free. As feedstock for manufacturers of extracts and oils, they are the key to the purest products possible. Because the trichomes collected with CryoMass technology represent only 10% or so of a plant’s weight and volume, they are cheaper to ship and store than gross plant material. For the same reason and because trichomes are free of the waxes and other unwanted materials found in the rest of the plant, processing trichomes into oils and extracts can be far quicker, cheaper and easier than processing gross plant material. Even trichomes captured from dried or frozen plant parts deliver this cost-saving advantage to processors of oils and extracts. The three-dimensional advantage achievable with the CryoMass system – first-stage cost savings, product enhancement and downstream cost savings – can as much as double a crop’s wholesale value. And in some jurisdictions, users may enjoy a reduction in excise taxes levied on cannabis and hemp harvests, which typically are tied to the gross weight of hemp or cannabis that is removed from the field. Production and processing of hemp and cannabis is a huge, worldwide industry. In the U.S., for example, the wholesale value of the cannabis crop from just the 11 states permitting adult-use and medical cannabis exceeds $6 billion annually. 1 And that may only be chapter one of the Company’s story. Several other high-value plants, including species that are important for health and wellness products, wrap their valuable elements in trichomes. The technology we are developing for hemp and cannabis may have profitable application to those other species as well. We intend to find out. In September, we were granted an additional patent for our process from the Chinese Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and several other international jurisdictions. On November 17 th

Variable Interest Entity

Variable Interest Entity	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Variable Interest Entity	2. Variable Interest Entity Pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Section 810 , Consolidation Under ASC 810, a reporting entity has a controlling financial interest in a VIE, and must consolidate that VIE, if the total equity investment at risk is not sufficient to permit the legal entity to finance its activities without additional subordinated financial support provided by any parties, including equity holders. Beginning July 15, 2019, the Company consolidated Critical Mass Industries LLC DBA Good Meds (“CMI” and/or “Good Meds”) as a VIE pursuant to certain intellectual property, administrative and consulting agreements in which the Company is deemed the primary beneficiary of CMI. Accordingly, the results of CMI have been included in the accompanying consolidated financial statements. Effective December 31, 2021, we entered into a restated and amended administrative services agreement, terminated our license and marketing agreements, and restated the asset purchase agreement with CMI and affiliates. As a result of these agreements, we disposed of all CMI-related assets and extinguished any and all related obligations. For clarity, we have no management or operations decision-making right or responsibility, nor any access to future economic benefits from operation of the assets. Therefore, upon commencing these agreements, we determined that CMI no longer qualifies as a variable interest entity as of December 31, 2021. CMI Statement of Operations For the Three Months Ended Description 2022 2021 Net sales $ - $ 1,695,925 Cost of goods sold, inclusive of depreciation - 1,118,735 Gross profit $ - $ 577,190 Operating expenses Personnel costs - 154,460 Sales and marketing - 226,347 General and administrative - 28,988 Legal and professional fees - 21,515 Total operating expenses - 431,310 Gain from operations $ - $ 145,880 Other income / (expense) Interest expense - (29,264 ) Total other income / (expense) - (29,264 ) Net loss - 116,616 As a result of new agreements entered with CMI on December 31, 2021, as further detailed in Note 1 above, we disposed of all CMI-related assets and extinguished any and all related obligations in exchange for a $3,600,000 promissory note due to us no later than December 31, 2023.	2. VARIABLE INTEREST ENTITY Pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Section 810 , Consolidation Under ASC 810, a reporting entity has a controlling financial interest in a VIE, and must consolidate that VIE, if the total equity investment at risk is not sufficient to permit the legal entity to finance its activities without additional subordinated financial support provided by any parties, including equity holders. Beginning July 15, 2019, the Company consolidated CMI as a VIE pursuant to certain intellectual property, administrative and consulting agreements in which the Company is deemed the primary beneficiary of CMI. Accordingly, the results of CMI have been included in the accompanying consolidated financial statements. Effective December 31, 2021, the Company entered into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes all assets and liabilities from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power to direct activities, absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI. CMI Assets & Liabilities As of December 31, Description 2021 2020 Current assets Cash and cash equivalents $ - $ 196,445 Accounts receivable, net - 66,043 Inventory, net - 791,868 Total current assets - 1,054,356 Total assets $ - $ 1,054,356 Current liabilities Accounts payable and accrued expenses $ - $ 211,463 Total current liabilities - 211,463 Total liabilities - 211,463 Net assets $ - $ 842,893 CMI Statement of Operations For the Years Ended Description 2021 2020 Net sales $ 5,891,894 $ 6,860,282 Cost of goods sold, inclusive of depreciation 4,132,696 4,901,237 Gross profit $ 1,759,198 $ 1,959,045 Operating expenses Personnel costs 428,728 402,389 Sales and marketing 816,683 908,502 General and administrative 112,934 231,376 Legal and professional fees 44,092 156,782 Amortization expense - 26,901 Total operating expenses 1,402,437 1,725,950 Gain from operations $ 356,761 $ 233,095 Other income / (expense) Interest expense (49,803 ) (153,592 ) Goodwill impairment - (4,663,514 ) Intangibles impairment - (361,218 Other income - - Total other income / (expense) (49,803 ) (5,178,324 ) Loss on disposal of discontinued operations (3,021,724 ) - Net income / (loss), before taxes (2,714,766 ) (4,945,229 ) Income taxes (10,235 ) (10,235 ) Net income / (loss), net of taxes $ (2,725,001 ) $ (4,955,464 ) As a result of new agreements entered with CMI on December 31, 2021, as further detailed in Note 1 above, we disposed of all CMI-related assets and extinguished any and all related obligations in exchange for a $3,600,000 promissory note due to us no later than December 31, 2023. When comparing the carrying value of CMI-related net assets to the value of the loan receivable, we calculated a loss on disposal of discontinued operations of $3,021,724.

Going Concern Uncertainty, Fina

Going Concern Uncertainty, Financial Conditions and Management’s Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Going Concern Uncertainty, Financial Conditions and Management’s Plans [Abstract]
Going Concern Uncertainty, Financial Conditions and Management’s Plans	3. Going Concern Uncertainty, Financial Conditions and Management’s Plans The Company believes it has sufficient cash available to fund its anticipated level of operations for at least the next twelve months. During the year ended 2021, the Company raised $10,548,535 in common stock and $4,900,000 in convertible notes which were all converted to common stock. While management believes the Company has sufficient cash available to support an anticipated level of operations for at least the next twelve months, the continuation of our company as a going concern is dependent upon the continued financial support from its shareholders, the ability of our company to obtain necessary equity or debt financing to continue operations, the payment of our note receivable from CMI , and ultimately the attainment of profitable operations. For the three months ended March 31, 2022, our company used $1,631,300 of cash for operating activities, incurred a net loss of $2,152,305 and has an accumulated deficit of $30,741,142 since inception. On March 11, 2020, the 2019 novel coronavirus (“COVID-19) was characterized as a “pandemic.” The Company’s operations were impacted during the year in the United States. The impact of COVID-19 developments and uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets. The Company assessed certain accounting matters that require consideration of forecasted financial information, including, but not limited to, the carrying value of the Company’s goodwill, intangible assets, and other long-lived assets, and valuation allowances in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2022 and through the date of this report. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Consolidated Financial Statements in future reporting periods. The COVID-19 pandemic and responses to this crisis, including actions taken by federal, state and local governments, have had an impact on the operations of the company, including, without limitation, the following: reduced staffing due to employee suspected conditions and social distancing measures; constraints on productivity; management and staff non-essential business-related travel was constrained due to stay-at-home orders; most employees have shifted to remote work resulting in loss of productivity; consumers visiting dispensaries operated under license impacted by stay-at-home orders. Management continues to monitor the COVID-19 pandemic situation and federal, state and local recommendations and will provide updates as appropriate.	3. GOING CONCERN UNCERTAINTY, FINANCIAL CONDITIONS AND MANAGEMENT’S PLANS The Company believes it has sufficient cash available to fund its anticipated level of operations for at least the next twelve months. During the year, the Company raised $10,548,535 in common stock and $4,900,000 in convertible notes which were all converted to common stock. While management believes the Company has sufficient cash available to support an anticipated level of operations for at least the next twelve months, the continuation of our company as a going concern is dependent upon the continued financial support from its shareholders, the ability of our company to obtain necessary equity or debt financing to continue operations, the sale of assets, and ultimately the attainment of profitable operations. For the year ended December 31, 2021, our company used $5,600,512 of cash for operating activities, incurred a net loss of $12,859,643 and has an accumulated deficit of $28,588,837 since inception. On March 11, 2020, the 2019 novel coronavirus (“COVID-19) was characterized as a “pandemic.” The Company’s operations were impacted during the year in the United States. The impact of COVID-19 developments and uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets. The Company assessed certain accounting matters that require consideration of forecasted financial information, including, but not limited to, the carrying value of the Company’s goodwill, intangible assets, and other long-lived assets, and valuation allowances in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2021 and through the date of this report. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Consolidated Financial Statements in future reporting periods. The COVID-19 pandemic and responses to this crisis, including actions taken by federal, state and local governments, have had an impact on the operations of the company, including, without limitation, the following: reduced staffing due to employee suspected conditions and social distancing measures; constraints on productivity; management and staff non-essential business-related travel was constrained due to stay-at-home orders; most employees have shifted to remote work resulting in loss of productivity; consumers visiting dispensaries operated under license impacted by stay-at-home orders. Management continues to monitor the COVID-19 pandemic situation and federal, state and local recommendations and will provide updates as appropriate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Cryomass Technologies Inc, Cryomass LLC, and CMI, a VIE for which the Company was deemed to be the primary beneficiary. All significant intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment from its corporate headquarters in Colorado. Effective December 31, 2021, the Company entered into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes all assets and liabilities from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power to direct activities, absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI. Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the fair value and potential impairment of inventory, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Reclassifications Certain items in the consolidated financial statements were reclassified from prior periods for presentation purposes. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturities of three months or less at the time of issuance to be cash equivalents. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable in conjunction with the disposal of discontinued operations at the end of 2021, which is backed by the assets of the discontinued operations, should the borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk. Purchase Accounting for Acquisitions We apply the acquisition method of accounting for a business combination. In general, this methodology requires us to record assets acquired and liabilities assumed at their respective fair values at the date of acquisition. Any amount of the purchase price paid that is in excess of the estimated fair value of the net assets acquired is recorded as goodwill. For certain acquisitions, we also record a liability for contingent consideration based on estimated future business performance. We monitor our assumptions surrounding these estimated future cash flows and, if there is a significant change, would record an adjustment to the contingent consideration liability and a corresponding adjustment to either income or expense. We determine fair value using widely accepted valuation techniques, primarily discounted cash flow and market multiple analyses. These types of analyses require us to make assumptions and estimates regarding industry and economic factors, the profitability of future business strategies, discount rates and cash flow. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future. If the contingent consideration paid for any of our acquisitions differs from the amount initially recorded, we would record either income or expense associated with the change in liability. Variable Interest Entities The Company accounts for variable interest entities in accordance with FASB ASC Topic 810, Consolidation Accounts Receivable, net Accounts receivable, net is comprised of balances due from customers and are recorded at the invoiced amount. Past due balances are determined based on the contractual terms of the arrangements. Accounts receivable are accrued against when management determines, after considering economic and business conditions and all means of collection efforts have been exhausted and the potential for recovery is considered remote, that the collection of receivables is doubtful. Inventory, net Inventory, net is comprised of work-in-process and finished goods consisting of cannabis and cannabidiol products. Cost includes expenditures directly related to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Inventory, net is stated at the lower of cost or net realizable value. The Company compares the cost of inventory with market value and writes down inventories to net realizable value, if lower. In evaluating whether inventories are stated at lower of cost or net realizable value, management considers such factors as inventories on hand, physical deterioration, obsolescence, changes in price levels, estimated time to sell such inventories and current market conditions. Due to changing market conditions, management will periodically conduct a thorough review of its inventory and record a provision for inventory losses if necessary. This is based on the Company’s best estimates of product sales prices and customer demand patterns. It is at least reasonably possible that the estimates used by the Company to determine its provision for inventory losses will be materially different from the actual amounts or results. These differences could result in materially higher than expected inventory provisions, which could have a materially adverse effect on the Company’s results of operations and financial conditions in the near term. Revenue Recognition Under FASB Topic 606, Revenue from Contacts with Customers Discontinued Operations For the three months ended March 31, 2021, Company’s revenue consisted of sales of cannabis and ancillary products to both retail consumers and wholesale customers. Revenue for retail customers was recognized upon completion of the transaction in the point of sale system and satisfaction of the sale by providing the corresponding inventory at the retail location. Revenue for wholesale customers was recognized upon acceptance of the physical goods and confirmation by acceptance of the inventory in the regulatory marijuana enforcement tracking reporting compliance (“METRC”) system. Revenue was recognized upon transfer of control of promised products to customers, generally as risk of loss passes, in an amount that reflected the consideration the Company expected to receive in exchange for those products. Taxes collected from customers, which was subsequently remitted to governmental authorities, were excluded from revenue. Retail customer loyalty liabilities were recognized in the period in which they were incurred and were often be retired without being utilized. Shipping and handling costs were expensed as incurred and are included in cost of sales. The Company operated in a highly regulated environment in which state regulatory approval was required prior to the customer being able to purchase the product, either through the Colorado Marijuana Enforcement Division for wholesale clients or the Colorado Department of Public Health and Environment for medical patients. Expenses Operating Expenses Operating expenses encompass personnel costs, sales and marketing expenses, research and development expenses, general and administrative expenses, professional and legal fees and depreciation and amortization related to the property and equipment and intangibles acquired through the acquisition of CMI and Cryocann. Personnel costs consist primarily of consulting expense and administrative salaries and wages. Sales and marketing expenses consist primarily of advertising and marketing, and salaries related to sales and marketing employees. General and administrative expenses are comprised of travel expenses, accounting expenses, and board fees. Professional services are principally comprised of outside legal and professional fees. Discontinued Operations Cost of Goods Sold, Net of Depreciation and Amortization Cost of goods sold primarily consisted of allocated salaries and wages of employees directly related with the production process, allocated depreciation and amortization directly related to the production process, cultivation supplies, rent and utilities. Other Expense, net Other expense, net consisted of interest expense, other income and (loss) gain on foreign exchange. Stock-Based Compensation The fair value of restricted stock units (“RSUs”) granted are measured on the grant date using the closing price of the Company’s common shares on the grant date. For stock options, the Company engages a valuation firm to calculate the grant date fair value of the options issued. The Company accounts for forfeitures as they occur, rather than estimating expected forfeitures over the course of a vesting period. All stock-based compensation costs are recorded in general and administrative expenses in the consolidated statements of operations. Property and Equipment, net Purchase of property and equipment are recorded at cost. Improvements and replacements of property and equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the consolidated statements of operations. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Computer equipment 3 – 5 years Furniture and fixtures 5 – 7 years Machinery and equipment 5 – 8 years Leasehold improvements Shorter of lease term Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of an acquired entity over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. Indefinite-lived intangible assets established in connection with business combinations consists of in process research and development. Intangible assets with indefinite lives are recorded at their estimated fair value at the date of acquisition. Once in process research and development is placed in service, it will be amortized over the estimated useful life. Intangible assets with finite lives are recorded at their estimated fair value at the date of acquisition and are amortized over their estimated useful lives using the straight-line method. Amortization of assets ceases upon designation as held for sale. The estimated useful lives of intangible assets are detailed in the table below: Estimated Patent 10 years In process research and development Indefinite Impairment of Goodwill and Intangible Assets Goodwill Goodwill is not amortized, but instead is tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of goodwill under the provisions of Financial Accounting Standards Board (FASB) Accounting Standard Update 2017-04 (“ASU 2017-04”), “ Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Intangibles – Goodwill and Other – Goodwill The Company performs impairment testing for goodwill by performing the following steps: 1) evaluate the relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, 2) if yes to step 1, calculate the fair value of the reporting unit and compare it with its carrying amount, including goodwill, 3) recognize impairment, limited to the total amount of goodwill allocated to that reporting unit, equal to the excess of the carrying value of a reporting unit over its fair value. Management concluded that there were no events indicative of goodwill impairment during the three months ended March 31, 2022. Indefinite-Lived Intangible Assets and Intangible Assets Subject to Amortization Indefinite-lived intangible assets and intangible assets subject to amortization are not amortized, but instead are tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of indefinite-lived intangible assets under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35, Intangibles – Goodwill and Other – General Intangibles Other Than Goodwill We account for the impairment of intangible assets subject to amortization under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Property, Plant, and Equipment Management concluded that there were no events indicative of identifiable intangible asset impairment during the three months ended March 31, 2022. Income Taxes The Company uses the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values reported in the consolidated balance sheets for cash, prepaid expenses, inventories, accounts payable, and notes payable approximate fair values because of the immediate or short-term maturities of these financial instruments. There were no other assets or liabilities that require fair value to be recalculated on a recurring basis. The fair value of beneficial conversion features associated with convertible notes and the fair value of warrants are calculated utilizing level 2 inputs. When multiple instruments are issued in a single transaction, the total proceeds from the transaction should be allocated among the individual freestanding instruments identified. The allocation occurs after identifying (1) all the freestanding instruments and (2) the subsequent measurement basis for those instruments. The subsequent measurement basis helps inform how the proceeds should be allocated. After the proceeds are allocated to the freestanding instruments, those instruments should be further evaluated for embedded features that may need to be bifurcated or separated. If debt or stock is issued with detachable warrants, the guidance in ASC 470-20-25-2 (applied by analogy to stock) requires that the proceeds be allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt or stock is issued with any other freestanding instrument that is classified in equity (such as a detachable forward contract) or as a liability but not subject to subsequent fair value accounting. Given that our convertible notes and common stock that were issued with warrants are both not subject to subsequent fair value accounting treatment, Management determined the relative fair value method shall be used for allocating the proceeds of the transaction. Under the relative fair value method, the instrument being analyzed is allocated a portion of the proceeds based on its fair value to the sum of the fair value of all the instruments covered int the allocation. Management additionally evaluates the facts and circumstances to determine whether the principal balance of convertible notes approximate their fair value, which we have concluded for all convertible notes issued. Net Loss per Share The Company follows ASC 260, Earnings Per Share Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40).	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Cryomass Technologies Inc, Cryomass LLC, and CMI, a VIE for which the Company was deemed to be the primary beneficiary. All significant intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment from its corporate headquarters in Colorado. Effective December 31, 2021, the Company entered into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes all assets and liabilities from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power to direct activities, absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI. Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the fair value and potential impairment of inventory, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Reclassifications Certain items in the consolidated financial statements were reclassified from prior periods for presentation purposes. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturities of three months or less at the time of issuance to be cash equivalents. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable in conjunction with the disposal of discontinued operations, which is backed by the assets of the discontinued operations, should the borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk. Purchase Accounting for Acquisitions We apply the acquisition method of accounting for a business combination. In general, this methodology requires us to record assets acquired and liabilities assumed at their respective fair values at the date of acquisition. Any amount of the purchase price paid that is in excess of the estimated fair value of the net assets acquired is recorded as goodwill. For certain acquisitions, we also record a liability for contingent consideration based on estimated future business performance. We monitor our assumptions surrounding these estimated future cash flows and, if there is a significant change, would record an adjustment to the contingent consideration liability and a corresponding adjustment to either income or expense. We determine fair value using widely accepted valuation techniques, primarily discounted cash flow and market multiple analyses. These types of analyses require us to make assumptions and estimates regarding industry and economic factors, the profitability of future business strategies, discount rates and cash flow. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future. If the contingent consideration paid for any of our acquisitions differs from the amount initially recorded, we would record either income or expense associated with the change in liability. Variable Interest Entities The Company accounts for variable interest entities in accordance with FASB ASC Topic 810, Consolidation Accounts Receivable, net Accounts receivable, net is comprised of balances due from customers and are recorded at the invoiced amount. Past due balances are determined based on the contractual terms of the arrangements. Accounts receivable are accrued against when management determines, after considering economic and business conditions and all means of collection efforts have been exhausted and the potential for recovery is considered remote, that the collection of receivables is doubtful. Accounts receivable amounts, net of allowance for doubtful accounts, were $0 and $606,043 as of December 31, 2021 and 2020, respectively. This includes $0 and $66,043, respectively, related to the VIE. Uncollectible accounts previously recorded as receivables are recognized as bad debt expense, with a corresponding decrease to accounts receivable. Bad debt expense was $541,099 and $188,548 for the years ended December 31, 2021 and 2020, respectively. This amount includes $1,099 and $4,548, respectively, related to the VIE, which is classified as discontinued operations. Inventory, net Inventory, net is comprised of work-in-process and finished goods consisting of cannabis and cannabidiol products. Cost includes expenditures directly related to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Inventory, net is stated at the lower of cost or net realizable value. The Company compares the cost of inventory with market value and writes down inventories to net realizable value, if lower. In evaluating whether inventories are stated at lower of cost or net realizable value, management considers such factors as inventories on hand, physical deterioration, obsolescence, changes in price levels, estimated time to sell such inventories and current market conditions. Due to changing market conditions, management conducted a thorough review of its inventory. As a result, a provision for inventory losses of $0 and $400,787 was charged against cost of goods sold during the years ended December 31, 2021 and 2020, respectively, due to a write down of inventory to its net realizable value. This was based on the Company’s best estimates of product sales prices and customer demand patterns. It is at least reasonably possible that the estimates used by the Company to determine its provision for inventory losses will be materially different from the actual amounts or results. These differences could result in materially higher than expected inventory provisions, which could have a materially adverse effect on the Company’s results of operations and financial conditions in the near term. Revenue Recognition Under FASB Topic 606, Revenue from Contacts with Customers Discontinued Operations The Company’s revenue consists of sales of cannabis and ancillary products to both retail consumers and wholesale customers. Revenue for retail customers is recognized upon completion of the transaction in the point of sale system and satisfaction of the sale by providing the corresponding inventory at the retail location. Revenue for wholesale customers is recognized upon acceptance of the physical goods and confirmation by acceptance of the inventory in the regulatory marijuana enforcement tracking reporting compliance (“METRC”) system. Revenue is recognized upon transfer of control of promised products to customers, generally as risk of loss passes, in an amount that reflects the consideration the Company expects to receive in exchange for those products. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from revenue. Retail customer loyalty liabilities are recognized in the period in which they are incurred and will often be retired without being utilized. Shipping and handling costs are expensed as incurred and are included in cost of sales, which were not material for the years ended December 31, 2021 and 2020. The Company operates in a highly regulated environment in which state regulatory approval is required prior to the customer being able to purchase the product, either through the Colorado Marijuana Enforcement Division for wholesale clients or the Colorado Department of Public Health and Environment for medical patients. Expenses Operating Expenses Operating expenses encompass personnel costs, sales and marketing expenses, general and administrative expenses, professional and legal fees and depreciation and amortization related to the property and equipment and intangibles acquired through the acquisition of CMI and Cryocann. Personnel costs consist primarily of consulting expense and administrative salaries and wages. Sales and marketing expenses consist primarily of advertising and marketing, and salaries related to sales and marketing employees. General and administrative expenses are comprised of travel expenses, accounting expenses, and board fees. Professional services are principally comprised of outside legal and professional fees. Discontinued Operations Cost of Goods Sold, Net of Depreciation and Amortization Cost of goods sold primarily consisted of allocated salaries and wages of employees directly related with the production process, allocated depreciation and amortization directly related to the production process, cultivation supplies, rent and utilities. Other Expense, net Other expense, net consisted of interest expense, other income and (loss) gain on foreign exchange. Stock-Based Compensation The fair value of restricted stock units (“RSUs”) granted are measured on the grant date using the closing price of the Company’s common shares on the grant date. For stock options, the Company engages a valuation firm to calculate the grant date fair value of the options issued. The Company accounts for forfeitures as they occur, rather than estimating expected forfeitures over the course of a vesting period. All stock-based compensation costs are recorded in general and administrative expenses in the consolidated statements of operations. Property and Equipment, net Purchase of property and equipment are recorded at cost. Improvements and replacements of property and equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the consolidated statements of operations. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Useful Life Computer equipment 3 – 5 years Furniture and fixtures 5 – 7 years Machinery and equipment 5 – 8 years Leasehold improvements Shorter of lease term or 15 years Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of an acquired entity over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. Indefinite-lived intangible assets established in connection with business combinations consists of in process research and development. Intangible assets with indefinite lives are recorded at their estimated fair value at the date of acquisition. Once in process research and development is placed in service, it will be amortized over the estimated useful life. Intangible assets with finite lives are recorded at their estimated fair value at the date of acquisition and are amortized over their estimated useful lives using the straight-line method. Amortization of assets ceases upon designation as held for sale. The estimated useful lives of intangible assets are detailed in the table below: Estimated Useful Life Patent 10 years In process research and development Indefinite Impairment of Goodwill and Intangible Assets Goodwill Goodwill is not amortized, but instead is tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of goodwill under the provisions of Financial Accounting Standards Board (FASB) Accounting Standard Update 2017-04 (“ASU 2017-04”), “ Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Intangibles – Goodwill and Other – Goodwill The Company performs impairment testing for goodwill by performing the following steps: 1) evaluate the relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, 2) if yes to step 1, calculate the fair value of the reporting unit and compare it with its carrying amount, including goodwill, 3) recognize impairment, limited to the total amount of goodwill allocated to that reporting unit, equal to the excess of the carrying value of a reporting unit over its fair value. During the year ended December 31, 2020, the Company concluded that goodwill resulting from the CMI transaction was impaired, resulting in a $4,663,514 impairment charge included in net loss from discontinued operations. In accordance with ASC 350, as of December 31, 2021, management concluded that the goodwill resulting from the Cryocann acquisition was not impaired. Indefinite-Lived Intangible Assets and Intangible Assets Subject to Amortization Indefinite-lived intangible assets and intangible assets subject to amortization are not amortized, but instead are tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of indefinite-lived intangible assets under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35, Intangibles – Goodwill and Other – General Intangibles Other Than Goodwill We account for the impairment of intangible assets subject to amortization under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Property, Plant, and Equipment During the year ended December 31, 2020, the Company concluded that intangible assets resulting from the CMI transaction were impaired, resulting in an impairment charge of $316,218, which is included in net loss from discontinued operations. As of December 31, 2021, management concluded that identifiable intangible assets resulting from the Cryocann transaction were not impaired. Contingencies An initial right-of-use (“ROU”) asset and corresponding liability of $1,411,461 was recognized upon the CMI Transaction. The Company adopted ASU Topic 842 January 1, 2019, but had no reportable operating leases at that point in time. As of December 31, 2021, our ROU assets and liabilities associated with CMI were no longer included on the consolidated balance sheets. Income Taxes The Company uses the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values reported in the consolidated balance sheets for cash, prepaid expenses, inventories, accounts payable, notes payable, and taxes payable approximate fair values because of the immediate or short-term maturities of these financial instruments. There were no other assets or liabilities that require fair value to be recalculated on a recurring basis. The fair value of beneficial conversion features associated with convertible notes and the fair value of warrants are calculated utilizing level 2 inputs. When multiple instruments are issued in a single transaction, the total proceeds from the transaction should be allocated among the individual freestanding instruments identified. In this case, there were warrants issued in conjunction with convertible notes of $4.9 million and $250K and the sale of common stock through subscription agreements for $679K and $10.3 million. The allocation occurs after identifying (1) all the freestanding instruments and (2) the subsequent measurement basis for those instruments. The subsequent measurement basis helps inform how the proceeds should be allocated. After the proceeds are allocated to the freestanding instruments, those instruments should be further evaluated for embedded features that may need to be bifurcated or separated. If debt or stock is issued with detachable warrants, the guidance in ASC 470-20-25-2 (applied by analogy to stock) requires that the proceeds be allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt or stock is issued with any other freestanding instrument that is classified in equity (such as a detachable forward contract) or as a liability but not subject to subsequent fair value accounting. Given that the convertible notes and common stock that were issued with warrants are both not subject to subsequent fair value accounting treatment, Management determined the relative fair value method shall be used for allocating the proceeds of the transaction. Under the relative fair value method, the instrument being analyzed is allocated a portion of the proceeds based on its fair value to the sum of the fair value of all the instruments covered int the allocation. Management additionally evaluated the facts and circumstances to determine whether the principal balance of the Notes ($4.9 million and $250K) approximated their fair value. The Notes were issued entirely to unrelated third parties which were deemed to be arm’s length transactions. In addition, the comparable interest rates for loans of similar companies as of the date of the Note issuances range from 10-15% given the liquidity concerns of the Company. The term of the Notes issued range from 8-15 months, which would support the conclusion that the principal balance approximates their fair value given the short-term maturities of each Note. Finally, the Warrants issued in connection with the Notes were included akin to a “sweetener” in the offering as opposed to compensation for adjusting the interest rate or other key terms within the Convertible Term Loan Agreements. As such, the Company concluded that the principal balance of the Notes approximated their fair value. The Warrants were initially measured at fair value and subsequent fair value measurement is not required as long as the instrument continues to be classified in equity. The proceeds from each transaction were allocated between the Notes and Warrants as well as common stock and Warrants based on the relative fair value method. Warrants issued in connection with cash provided for common shares, and not convertible notes, during the fourth quarter of 2021 also followed the same fair value assessment and treatment as noted above. Net Loss per Share The Company follows ASC 260, Earnings Per Share Assets and Liabilities of Discontinued Operations Held for Sale Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets (and liabilities) are classified as held for sale in the balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation of assets ceases upon designation as held for sale. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (ASC 350), In February 2016, the FASB issued ASU No. 2016-02, Leases

Revenue Recognition

Revenue Recognition	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	5. Revenue Recognition Disaggregated Revenue The following amounts relate to discontinued operations from our CMI VIE disposed of on December 31, 2021. For the Three Months Ended 2022 2021 Types of Revenues: Medical retail $ - $ 1,130,504 Medical wholesale - 556,310 Recreational wholesale - 9,010 Total revenues $ - $ 1,130,504	5. REVENUE RECOGNITION Disaggregated Revenue For the Years Ended 2021 2020 Types of Revenues: Medical retail $ - $ 11,200 Medical wholesale - 700 Recreational wholesale - 769,555 Total revenues $ - $ 781,455

Business Combination

Business Combination	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Business Combinations [Abstract]
Business Combination	6. Business Combination On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann (the “Cryocann Acquisition”). The aggregate purchase price was $3,500,000 million in cash and 10,000,000 shares of Company common stock and a promissory note was issued for $1,252,316 payable by Company to Cryocann on October 15, 2021, which represents the remaining Purchase Price of $2,500,000 minus the amount owed by Cryocann under a Loan Agreement dated April 23, 2021 by and between Cryocann and the Company. The Company concluded that the Cryocann Acquisition qualified as a business combination under ASC 805. The Company’s allocation of the purchase price was calculated as follows: Cash $ 2,247,684 Common stock 1,804,500 Promissory Note 1,220,079 Total purchase price $ 5,272,263 Description Fair Value Weighted Assets acquired: Intangible assets: In process research and development 3,209,000 Indefinite Patent 873,263 10 Goodwill 1,190,000 Total assets acquired $ 5,272,263 As if the acquisition occurred on January 1, 2021, as reported in our pro forma basis, our net loss would have been $2,025,847 and our net loss per common share would have been $0.02 for the three months ended March 31, 2021. Our net sales would have remained unchanged during the period. These pro forma results are not necessarily indicative of the results that actually would have occurred if the acquisition had occurred on the first day of the periods presented, nor does the pro forma financial information purport to represent the results of operations for future periods.	6. BUSINESS COMBINATIONS Effective June 23, 2021, the Company acquired substantially all the assets of Cryocann for $3,500,000 million in cash and 10,000,000 shares of Company common stock, of which $1,000,000 in cash and 10,000,000 shares of Company common stock were paid at closing and a promissory note was issued for $1,252,316 payable by Company to Cryocann on October 15, 2021, which represents the remaining Purchase Price of $2,500,000 minus the amount owed by Cryocann under a Loan Agreement dated April 23, 2021 by and between Cryocann and the Company. The Company concluded that the Cryocann Acquisition qualified as a business combination under ASC 805. The Company’s allocation of the purchase price was calculated as follows: Cash $ 2,247,684 Common stock 1,804,500 Promissory Note 1,220,079 Total purchase price $ 5,272,263 Description Fair Value Weighted Assets acquired: Intangible assets: In process research and development 3,209,000 Indefinite Patent 873,263 10 Goodwill 1,190,000 Total assets acquired $ 5,272,263 The following table below represents the revenue, net loss and loss per share effect of the acquired company, as reported in our pro forma basis as if the acquisition occurred on January 1, 2021. These pro forma results are not necessarily indicative of the results that actually would have occurred if the acquisition had occurred on the first day of the periods presented, nor does the pro forma financial information purport to represent the results of operations for future periods. For the Years Ended 2022 2021 Net Sales $ 7,641,737 $ 7,641,737 Net loss $ (12,417,483 ) $ (12,417,483 ) Net loss per common share $ (0.08 ) $ (0.08 )

Discontinued Operations

Discontinued Operations	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	7. Discontinued Operations In June 2020, the Company’s board of directors adopted a plan to exit the cultivation, manufacturing of infused products and retail distribution businesses through the sale of CMI. The Company determined that the intended sale represented a strategic shift that will have a major effect on the Company’s operations and financial results. The consolidated statements of operations include the following operating results related to these CMI discontinued operations: Three Months Ended 2022 2021 Net sales $ - $ 1,695,925 Cost of goods sold, inclusive of depreciation - 1,118,735 Gross profit - 577,190 Operating expenses: Personnel costs - 154,460 Sales and marketing - 226,347 General and administrative - 28,988 Legal and professional fees - 21,515 Total operating expenses - 431,310 Gain / (loss) from operations - 145,880 Other income (expenses): Interest expense - (29,264 ) Total other expenses - (29,264 ) Net gain / (loss) from discontinued operations, before taxes - 116,616 Income taxes - - Net gain / (loss) from discontinued operations $ - $ 116,616	7. DISCONTINUED OPERATIONS In June 2020, the Company’s board of directors adopted a plan to exit the cultivation, manufacturing of infused products and retail distribution businesses through the sale of CMI. The Company determined that the intended sale represented a strategic shift that will have a major effect on the Company’s operations and financial results. The accompanying consolidated balance sheets include the following carrying amounts of assets and liabilities related to these CMI discontinued operations: December 31, December 31, Assets Accounts receivable, net $ - $ 66,043 Prepaid expenses - 7,601 Inventory, net - 791,868 Property and equipment, net - 2,714,771 Goodwill - - Intangible assets, net - 2,481,128 Security deposits - 11,522 Right of use asset, net - 794,907 Total current assets held for sale - 6,867,840 Total assets held for sale $ - $ 6,867,840 Liabilities Accounts payable and accrued expenses - 211,463 Taxes payable - 22,645 Notes payable, related parties - 458,599 Right of use liability - 771,578 Total liabilities held for sale - 1,464,285 Net assets $ - $ 5,403,555 The consolidated statements of operations include the following operating results related to these CMI discontinued operations: Year Ended 2021 2020 Net sales $ 5,891,894 $ 6,860,282 Cost of goods sold, inclusive of depreciation 4,132,696 4,901,237 Gross profit 1,759,198 1,959,045 Operating expenses: Personnel costs 428,728 402,389 Sales and marketing 816,683 908,502 General and administrative 112,934 231,376 Legal and professional fees 44,092 156,782 Amortization expense - 26,901 Total operating expenses 1,402,437 1,725,950 Gain from operations 356,761 233,095 Other income (expenses): Interest expense (49,803 ) (153,592 ) Goodwill impairment - (4,663,514 ) Intangibles impairment - (361,218 ) Other income - - Total other income (expenses) (49,803 ) (5,178,324 ) Loss on disposal of discontinued operations (3,021,724 ) (4,945,229 ) Net gain / (loss) from discontinued operations, before taxes (2,714,766 ) (4,945,229 ) Income taxes (10,235 ) (10,235 ) Net gain / (loss) from discontinued operations $ (2,725,001 ) $ (4,955,464 ) As discussed in Note 2, we disposed of all CMI-related assets and extinguished any and all related obligations, resulting in a loss on disposal of discontinued operations of $3,021,724.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	8. Property and Equipment, Net Property and equipment, net consisted of the following. March 31, December 31, Leasehold improvements $ - $ - Machinery and equipment 233,641 225,000 Furniture and fixtures - - Construction in progress - - 233,641 225,000 Less: Accumulated depreciation - - $ 233,641 $ 225,000 As of March 31, 2022, our machinery and equipment was not capable of producing a unit of product that is saleable. Depreciation expense will be recognized once our machinery and equipment is ready for its intended use.	8. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following. December 31, December 31, Leasehold improvements $ - $ 2,770,385 Machinery and equipment 225,000 1,065,885 Furniture and fixtures - 43,331 Construction in progress - 227,995 225,000 4,107,596 Less: Accumulated depreciation - (1,392,825 ) $ 225,000 $ 2,714,771 Depreciation expense for the years ended December 31, 2021 and 2020 was $0 and $131,110, respectively. Depreciation expense was recorded in cost of goods sold and general and administrative expense and is included in discontinued operations.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets The carrying value of goodwill was $1,190,000 as of March 31, 2022 and December 31, 2021. The following tables summarize information relating to the Company’s identifiable intangible assets as of March 31, 2022 and December 31, 2021: March 31, 2022 Estimated Gross Accumulated Carrying Amortized Patent 10 years $ 873,263 $ (65,495 ) $ 807,768 Indefinite-lived In-process research and development Indefinite 3,209,000 - 3,209,000 Total identifiable intangible assets $ 4,082,263 $ (65,495 ) $ 4,016,768 December 31, 2021 Estimated Gross Accumulated Carrying Amortized Patent 10 years $ 873,263 $ (43,663 ) $ 829,600 Indefinite-lived In-process research and development Indefinite 3,209,000 - 3,209,000 Total identifiable intangible assets $ 4,082,263 $ (43,663 ) $ 4,038,600 Amortization expense was $21,832 and $0 for the three months ended March 31, 2022 and 2021, respectively.	9. GOODWILL AND INTANGIBLE ASSETS The carrying value of goodwill was $1,190,000 and $0, as of December 31, 2021 and December 31, 2020, respectively. The following tables summarize information relating to the Company’s identifiable intangible assets as of December 31, 2021. The Company had no identifiable intangible assets as of December 31, 2020. Estimated Gross Accumulated Amortization Carrying Amortized Patent 10 years 873,263 (43,663 ) 829,600 Indefinite-lived In-process research and development Indefinite 3,209,000 - 3,209,000 Total identifiable intangible assets $ 4,082,263 $ (43,663 ) $ 4,038,600 Amortization expense, which is included in continuing operations, was $43,663 and $0 for the years ended December 31, 2021 and 2020, respectively.

Loan Receivable

Loan Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Loan Receivable [Abstract]
Loans Receivable	10. Loans Receivable As a result of new agreements entered with CMI on December 31, 2021, as further detailed in Note 1 above, we received a $3,600,000 promissory note due to us no later than December 31, 2023. In consideration of the loan receivable, we conveyed to CMI, any and all manufacturing, grow equipment, retail-related assets and other assets Seller owns in the state of Colorado and are currently used by CMI subsidiaries in the course of business, including client lists and appertaining intellectual property, and no other Buyer or Parent assets, as well as all liabilities related to these assets. During the quarter, the Company issued an additional $620,000 in loans to CMI.	10. LOAN RECEIVABLE As a result of new agreements entered with CMI on December 31, 2021, as further detailed in Note 1 above, we received a $3,600,000 promissory note due to us no later than December 31, 2023. In consideration of the loan receivable, we conveyed to CMI, any and all manufacturing, grow equipment, retail-related assets and other assets Seller owns in the state of Colorado and are currently used by CMI subsidiaries in the course of business, including client lists and appertaining intellectual property, and no other Buyer or Parent assets, as well as all liabilities related to these assets.

Debt

Debt	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	11. Debt On July 27, 2020, the Company entered into a subscription agreement consisting of 1) a convertible note and 2) warrants. The 1) convertible note has a face value of $250,000, matures August 1, 2022, and accrues interest at 8% per annum. The note is convertible into 2,500,000 shares of the Company’s common stock at a conversion price of $0.10 per share. The beneficial conversion feature is accounted for in accordance with ASC 470-20 Debt with Conversion and Other Options On August 26, 2020, the Company entered into a $600,000 loan agreement, which accrues interest at 84% per annum. On January 25, 2021, the Company refinanced this loan at 93.6%, to obtain additional funding. The loan was fully repaid on April 27, 2021. On March 18, 2021, the Company entered into a $225,000 note payable, which accrued interest at 15% per annum. The note was fully repaid on May 7, 2021. Between March 29, 2021 and July 6, 2021, the Company entered into a series of similar subscription agreements with either domestic or non-US accredited investors, respectively (each, a “Initial Tranche Subscription Agreement (US)” and, respectively, “Initial Tranche Subscription Agreement (non-US)”) pursuant to which the Company issued and sold to certain accredited investors, in the initial tranche of a non-brokered private placement (the “Private Placement”), an aggregate 3,000 units (“Units”), each Unit representing (i) one $1,000 principal amount term note providing for an optional conversion into shares of Company common stock at a price of $0.20 per share (each the “Initial Convertible Term Note”) and (ii) a common share warrant for the purchase of 5,000 shares of Company common stock at an exercise price of $0.40 per share (each an “Initial Warrant”), for aggregate net proceeds of $3,000,000. The Initial Convertible Term Notes and the Initial Warrants mature on March 31, 2022 and March 31, 2023, respectively, and accrued interest at a rate of 12% per annum payable on a quarterly basis. Between May and July 6, 2021, the Company entered into a series of substantially similar subscription agreements with either domestic or non-US investors (each, a “Subscription Agreement (US)”, and, respectively, “Subscription Agreement (non-US)”) pursuant to which the Company issued and sold to certain accredited investors, in the second tranche of the Private Placement, an aggregate 1,900 units (“Units”), each Unit representing (i) one $1,000 principal amount term note (each a “Convertible Term Note”) providing for an optional conversion into shares of Company common stock at a price of $0.20 per share and (ii) a common share warrant for the purchase of 5,000 shares of Company common stock at an exercise price of $0.40 per share (each a “Warrant”), for additional aggregate net proceeds of $1,900,000. The Convertible Term Notes and Warrants mature on September 30, 2022 and April 30, 2023, respectively, and accrued interest at a rate of 12% per annum payable on a quarterly basis. All notes were converted during the fourth quarter of 2021. On August 20, 2021, the Company entered into a $300,000 loan agreement, which accrued interest at 91.23% per annum. Payment is due on a weekly basis up to the maturity date of May 27, 2021. The loan was fully repaid on October 19, 2021.	11. DEBT On July 27, 2020, the Company entered into a subscription agreement consisting of 1) a convertible note and 2) warrants. The 1) convertible note has a face value of $250,000, matures August 1, 2022, and accrues interest at 8% per annum. The note is convertible into 2,500,000 shares of the Company’s common stock at a conversion price of $0.10 per share. The beneficial conversion feature is accounted for in accordance with ASC 470-20 Debt with Conversion and Other Options On August 26, 2020, the Company entered into a $600,000 loan agreement, which accrues interest at 84% per annum. On January 25, 2021, the Company refinanced this loan at 93.6%, to obtain additional funding. The loan was fully repaid on April 27, 2021, with a $412,560 loan balance as of December 31, 2020. On March 18, 2021, the Company entered into a $225,000 note payable, which accrued interest at 15% per annum. The note was fully repaid on May 7, 2021. Between March 29, 2021 and July 6, 2021, the Company entered into a series of similar subscription agreements with either domestic or non-US accredited investors, respectively (each, a “Initial Tranche Subscription Agreement (US)” and, respectively, “Initial Tranche Subscription Agreement (non-US)”) pursuant to which the Company issued and sold to certain accredited investors, in the initial tranche of a non-brokered private placement (the “Private Placement”), an aggregate 3,000 units (“Units”), each Unit representing (i) one $1,000 principal amount term note providing for an optional conversion into shares of Company common stock at a price of $0.20 per share (each the “Initial Convertible Term Note”) and (ii) a common share warrant for the purchase of 5,000 shares of Company common stock at an exercise price of $0.40 per share (each an “Initial Warrant”), for aggregate net proceeds of $3,000,000. The Initial Convertible Term Notes and the Initial Warrants mature on March 31, 2022 and March 31, 2023, respectively, and accrued interest at a rate of 12% per annum payable on a quarterly basis. Between May and July 6, 2021, the Company entered into a series of substantially similar subscription agreements with either domestic or non-US investors (each, a “Subscription Agreement (US)”, and, respectively, “Subscription Agreement (non-US)”) pursuant to which the Company issued and sold to certain accredited investors, in the second tranche of the Private Placement, an aggregate 1,900 units (“Units”), each Unit representing (i) one $1,000 principal amount term note (each a “Convertible Term Note”) providing for an optional conversion into shares of Company common stock at a price of $0.20 per share and (ii) a common share warrant for the purchase of 5,000 shares of Company common stock at an exercise price of $0.40 per share (each a “Warrant”), for additional aggregate net proceeds of $1,900,000. The Convertible Term Notes and Warrants mature on September 30, 2022 and April 30, 2023, respectively, and accrued interest at a rate of 12% per annum payable on a quarterly basis. During the year ended December 31, 2021, we recorded a $1,444,542 debt discount associated on the $4,900,000 of convertible notes, comprised of additional paid in capital for the fair value of warrants and a beneficial conversion feature of $928,779 and $515,763, respectively. All notes were converted during the year ended December 31, 2021, and the entire debt discount was amortized into interest expense during the year. On August 20, 2021, the Company entered into a $300,000 loan agreement, which accrues interest at 91.23% per annum. Payment is due on a weekly basis up to the maturity date of May 27, 2021. The loan was fully repaid on October 19, 2021.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions In conjunction with the Cryocann Acquisition, the Company received a promissory note from Matt Armstrong, an employee of the Company, for $281,771. This note receivable was issued as part of an employment agreement with Matt Armstrong, effective June 22, 2021, and was offset against his signing bonus on October 15, 2021. There was no interest associated with the note. On August 19, 2021, the Company entered into a loan agreement of $237,590 with its Chief Executive Officer, Christian Noel. The note accrues interest at 14% per annum and was repaid on October 22, 2021. On November 15, 2021, the Company issued 250,000 common shares and warrants, respectively, to Christian Noel in exchange for $50,000. In addition, the Company issued 760,000 common shares and warrants, respectively, to Trichome Capital Inc. in exchange for $152,000. Christian Noel has voting and investment control of Trichome Capital Inc.	12. RELATED PARTY TRANSACTIONS In conjunction with the CMI Transaction, the Company assumed a note payable in which the note holder, John Knapp (“Knapp”) is a significant shareholder in the Company. In the second quarter of 2021, the Company issued 2,500,000 shares to pay off the balance of the note. Effective February 25, 2020, Knapp resigned as a director of Cryomass Technologies, at which time 200,000 Restricted Stock Units were deemed to have vested and were converted into 200,000 common shares. Refer to Note 2 for additional details on the relationship of CMI as a VIE. The outstanding balance of the notes payable, related party was $0 and $458,599 as of December 31, 2021 and December 31, 2020, respectively. In conjunction with the Cryocann Acquisition, the Company received a promissory note from Matt Armstrong, an employee of the Company, for $281,771. This note receivable was issued as part of an employment agreement with Matt Armstrong, effective June 22, 2021, and was offset against his signing bonus on October 15, 2021. There was no interest associated with the note. On August 19, 2021, the Company entered into a loan agreement of $237,590 with its Chief Executive Officer, Christian Noel. The note accrues interest at 14% per annum and was repaid on October 22, 2021. On November 15, 2021, issued 250,000 common shares and warrants, respectively, to Christian Noel in exchange for $50,000.

Shareholders' Equity

Shareholders' Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Shareholders' Equity	13. Shareholders’ Equity From January to March 2021, the Company issued 1,491,819 shares of common stock in order to raise capital. From April to June 2021, the Company issued 10,000,000 shares of common stock related to the CryoCann transaction, 6,903,172 shares of common stock pursuant to employment agreements, 2,500,000 shares of common stock in exchange for the extinguishment of debt, and 633,125 shares of common stock in exchange for services. From July to September 2021, the Company issued 798,414 shares of common stock in order to raise capital, 633,707 shares of common stock in exchange for services, and 92,127 shares of common stock for interest payment on a note payable. From October to December 2021, the Company issued 50,700,000 shares of common stock in order to raise capital, 1,570,501 shares of common stock in exchange for services, and 24,621,119 shares of common stock in exchange for extinguishment of debt. From January to March 2022, the Company issued 458,334 shares of common stock in exchange for services, 550,000 shares of common stock for 2021 management performance bonuses, 185,529 shares of common stock for director compensation, and 1,000,000 shares of common stock for 2020 RSU grants vesting in January 2022. Restricted Stock Unit Awards The Company adopted its 2019 Omnibus Stock Incentive Plan (the “2019 Plan”), which provides for the issuance of stock options, stock grants and RSUs to employees, directors and consultants. The primary purpose of the 2019 Plan is to enhance the ability to attract, motivate, and retain the services of qualified employees, officers and directors. Any RSUs granted under the 2019 Plan will be at the discretion of the Compensation Committee of the Board of Directors. On January 10, 2022, the shareholders approved the 2022 Stock Incentive Plan which then replaced the 2019 Plan. A summary of the Company’s RSU award activity for the three months ended March 31, 2022 is as follows: Restricted Weighted Outstanding at December 31, 2021 2,200,003 $ 0.45 Granted 1,469,511 0.27 Vested (1,735,529 ) 0.49 Forfeited - - Outstanding at March 31, 2022 1,933,982 $ 0.27 The total fair value of RSUs vested during the three months ending March 31, 2022 and 2021 was $848,600 and $146,602, respectively. As of March 31, 2022 and 2021, there was $187,761 and $472,087, respectively, of unrecognized stock-based compensation cost related to non-vested RSU’s, which is expected to be recognized over the remaining vesting period. Stock-based compensation expense relating to RSU’s was $140,815 and $250,817 for the three months ending March 31, 2022 and 2021, respectively. Stock-based compensation for the three months ending March 31, 2022 consisted of equity awards forfeited, granted and vested to employees, directors and consultants of the Company in the amount of $27,179, $108,771, and $4,866, respectively. Expenses for stock-based compensation are included on the accompanying consolidated statements of operations in general and administrative expense. Stock Option Awards A summary of the Company’s stock option activity for the three months ended March 31, 2022 is as follows: Stock Weighted Weighted Aggregate Outstanding at December 31, 2021 8,500,000 $ 0.18 9.2 $ 1,579,108 Granted and vested - - - - Forfeited - - - - Outstanding at March 31, 2022 8,500,000 $ 0.18 9.0 $ 1,579,108 During the three months ended March 31, 2022 and 2021, the Company did not issue any stock options. During the year ended December 31, 2021, the Company issued warrants with the option to purchase 73,950,000 common shares at an exercise price of $0.40 per share. Of these warrants, 15,000,000 shares expire on March 31, 2023, 9,500,000 expire on April 30, 2023, 1,000,000 expire on September 17, 2023, 7,750,000 expire on October 15, 2023, 9,510,000 expire on October 26, 2023, 190,000 expire on November 2, 2023, 27,060,000 expire on November 10, 2023, 1,940,000 expire on November 15, 2023, and 750,000 expire on November 17, 2023. The fair value of these warrants is $1,867,960, which is reflected in additional paid in capital.	13. SHAREHOLDERS’ EQUITY From June to August 2019, the Company completed a private placement for the sale of its common stock. The Company issued 14,325,005 shares of common stock for gross proceeds of $7,162,503, or $0.50 per share, minus equity issuance costs of $72,096. In July 2019, the Company issued 13,553,233 shares of common stock in connection with the CMI Transaction (refer to Note 6). During the year ended December 31, 2019, the Company issued 790,000 shares of common stock pursuant to advisory agreements. The fair value of $395,000 was included in legal and professional fees in the consolidated statements of operations. In February 2020, the Company issued 400,000 shares of common stock pursuant to accelerated vesting of RSU’s upon the resignation of a former executive. In February 2020, the Company issued 200,000 shares of common stock pursuant to accelerated vesting of RSU’s upon the resignation of a former board member. In March 2020, the Company issued 1,175,549 shares of common stock to a former executive per a separation agreement. In June 2020, four shareholders submitted 15,050,000 shares of common stock for cancellation pursuant to prior agreements among certain shareholders. Accordingly, the Company cancelled 15,050,000 shares of common stock. In July 2020, the Company issued 10,000 shares of common stock to a former employee per a separation agreement. In July 2020, one shareholder submitted 300,000 shares of common stock for cancellation pursuant to prior agreements. Accordingly, the Company cancelled 300,000 shares of common stock. In August 2020, the Company issued 60,000 shares of common stock in order to raise capital. In August 2020, the Company issued 757,895 shares of common stock to former board members per a separation agreement. From October to December 2020, the Company issued 3,535,665 shares of common stock in order to raise capital. From January to March 2021, the Company issued 1,491,819 shares of common stock in order to raise capital. From April to June 2021, the Company issued 10,000,000 shares of common stock related to the CryoCann transaction, 6,903,172 shares of common stock pursuant to employment agreements, 2,500,000 shares of common stock in exchange for the extinguishment of debt, and 633,125 shares of common stock in exchange for services. From July to September 2021, the Company issued 798,414 shares of common stock in order to raise capital, 633,707 shares of common stock in exchange for services, and 92,127 shares of common stock for interest payment on a note payable. From October to December 2021, the Company issued 50,700,000 shares of common stock in order to raise capital, 1,570,501 shares of common stock in exchange for services, and 24,621,119 shares of common stock in exchange for extinguishment of debt. Restricted Stock Unit Awards The Company adopted its 2019 Omnibus Stock Incentive Plan (the “2019 Plan”), which provides for the issuance of stock options, stock grants and RSUs to employees, directors and consultants. The primary purpose of the 2019 Plan is to enhance the ability to attract, motivate, and retain the services of qualified employees, officers and directors. Any RSUs granted under the 2019 Plan will be at the discretion of the Compensation Committee of the Board of Directors. In April 2021 Board of Directors cancelled the 2019 Plan. A summary of the Company’s RSU award activity for the year ended December 31, 2021 is as follows: Restricted Stock Weighted Outstanding at December 31, 2020 2,453,175 $ 0.45 Granted 6,650,000 0.15 Vested (6,903,172 ) 0.15 Forfeited - - Outstanding at December 31, 2021 2,200,003 $ 0.45 The total fair value of RSUs vested during the years ending December 31, 2021 and 2020 was $2,851,102 and $309,790, respectively. As of December 31, 2021 and 2020, there was $78,676 and $600,241, respectively, of unrecognized stock-based compensation cost related to non-vested RSU’s, which is expected to be recognized over the remaining vesting period. Stock-based compensation expense relating to RSU’s was $1,685,066 and $734,752 for the years ending December 31, 2021 and 2020, respectively. Stock-based compensation for the year ending December 31, 2021 consisted of equity awards forfeited, granted and vested to employees, directors and consultants of the Company in the amount of $1,272,779, $347,275, and $65,012, respectively. Stock Option Awards A summary of the Company’s stock option activity for the year ended December 31, 2021 is as follows: Stock Weighted Weighted Aggregate Outstanding at December 31, 2020 3,500,000 $ 0.16 8.8 $ 581,591 Granted and vested 5,000,000 0.20 9.5 987,517 Forfeited - - - - Outstanding at December 31, 2021 8,500,000 $ 0.18 9.2 $ 1,579,108 During the years ended December 31, 2021 and 2020, the Company issued 5,000,000 and 3,500,000, respectively, of stock options to certain employees, which vested immediately, for a total fair value of $968,205 and $555,532, respectively. Stock-based compensation expense relating to stock options was $968,205 and $555,532, respectively. Expenses for stock-based compensation is included on the accompanying consolidated statements of operations in general and administrative expense. During the year ended December 31, 2021, the Company issued warrants with the option to purchase 73,950,000 common shares at an exercise price of $0.40 per share. Of these warrants, 15,000,000 shares expire on March 31, 2023, 9,500,000 expire on April 30, 2023, 1,000,000 expire on September 17, 2023, 7,750,000 expire on October 15, 2023, 9,510,000 expire on October 26, 2023, 190,000 expire on November 2, 2023, 27,060,000 expire on November 10, 2023, 1,940,000 expire on November 15, 2023, and 750,000 expire on November 17, 2023. The fair value of these warrants is $1,867,960, which is reflected in additional paid in capital. During the year ended December 31, 2020, the Company issued 2,500,000 and 4,525,898 warrant shares at an excersice price of $0.25 and $0.30, respectively, which expire on August 1, 2022 and November 22, 2022, respectively. The fair value of these warrants is $266,383, which is reflected in additional paid in capital.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes In accordance with ASC 740-270, the Company calculates the interim tax expense based on an annual effective tax rate (“AETR”). The AETR represents the Company’s estimated effective tax rate for the year based on full year projection of tax expense, divided by the projection of full year pretax book loss, adjusted for discrete transactions occurring during the period. The annual effective tax rate for the three months ended March 31, 2022 was 0.0%, As of March 31, 2022, the Company has recorded no income tax liability.	14. INCOME TAXES Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in the tax laws and rates on the date of enactment. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. The amounts in the following table are included in net loss from discontinued operations, net of tax. The provision (benefit) for income taxes for the years ended December 31, 2021 and 2020 consists of: 2021 2020 Current (benefit) provision Federal $ - $ - State - - Total Current - - Deferred (benefit) provision Federal $ 3,724 $ 3,724 State 6,511 6,511 Total Deferred $ 10,235 $ 10,235 Total Provision $ 10,235 $ 10,235 The statutory federal income tax rate (21 percent) for the years ended December 31, 2021 and 2020 is reconciled to the effective income tax rate as follows: 2021 2020 Tax Percentage Tax Percentage Income Taxes At Statutory Federal Income Tax Rate $ (2,202,256 ) 21.00 % $ (2,517,221 ) 21.00 % State Taxes, Net Of Federal Income Tax Benefit 6,511 (0.06 ) 6,511 (0.05 ) Meals & Entertainment - 0.00 261 0.00 ) Penalties and Fines - 0.00 - 0.00 Return to Provision Adjustment - Permanent Items - 0.00 - 0.00 Deferred Only Adjustment - 0.00 (228,539 ) 1.91 Change in Valuation Allowance 1,838,803 (17.53 ) 200,791 (1.68 ) Section 280E Expense Disallowance 367,177 (3.50 ) 2,548,431 (21.26 ) Other - 0.00 - 0.00 Effective tax $ 10,235 (0.10 )% $ 10,235 (0.09 )% Deferred tax assets and liabilities by type at December 31, 2021 and 2020 are as follows: Deferred Tax Assets (Liabilities): 2021 2020 Stock Compensation $ (7,335 ) $ 62,606 Stock Compensation - Options 259,057 - Accrued Salary 44,384 - Trademark/Trade Name (8,033 ) (4,765 ) Developed Manufacturing Process - Extraction (53,747 ) (31,884 ) Customer Relationships 1,947 1,158 Patent 3,589 - In-Process Research & Development - CryoCann (26,376 ) - Goodwill - CMI 179,892 168,688 In-Process Research & Development - CMI 98,135 105,985 Goodwill - CryoCann 3,490 - NOL - Federal Pre-2018 43,367 43,367 NOL - Federal Post-2017 2,097,542 377,529 NOL - State 608,703 294,183 Deferred Tax Assets (Liabilities) $ 3,244,615 $ 1,016,867 Valuation Allowance (3,269,776 ) (1,031,792 ) Net Deferred Tax Assets (Liabilities) $ (25,160 ) $ (14,926 ) At December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of approximately $10,194,806 and $2,004,266 that may be offset against future taxable income from the years 2022 through 2041. State net operating losses were approximately $16,641,692 and $8,042,840 at December 31, 2021 and 2020. However, as a result of the 2017 Tax Cuts and Jobs Act (“TCJA”) and the 2020 Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), any federal net operating losses generated in years beginning after December 31, 2017 and before January 1, 2022 can be carried forward indefinitely to offset taxable income in future periods. The amount of NOLs with no expiration totaled $9,988,297 as of December 31, 2021. The deferred tax assets before valuation allowance for the net operating losses were $2,749,613 and $715,079 as of December 31, 2021 and 2020. Should a change in ownership occur, the NOLs would be subject to the limitations set forth under IRC Section 382. Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. On the basis of this evaluation, as of December 31, 2021, the Company has recorded a full valuation allowance against its net deferred tax assets. The valuation allowance is estimated to be approximately $3,269,776 and $1,031,792 for the years ended December 31, 2021 and 2020, respectively. However, because deferred tax liabilities related to indefinite lived intangibles cannot be used as a source of income to recognize deferred tax assets with definite lives, the recorded valuation allowance exceeded the net deferred assets resulting in an overall net deferred tax liability, as reflected in the table above. The Company has adopted the provisions of ASC 740 which prescribe the procedures for recognition and measurement of tax positions taken or expected to be taken in income tax returns. As of December 31, 2021, the Company does not have an accrual relating to uncertain tax positions. It is not anticipated that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.

Commitments & Contingencies

Commitments & Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	15. Commitments & Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Lease Commitments The Company accounts for lease transactions in accordance with Topic 842, Leases There are no other leases that meet the reporting standards of ASU Topic 842 as the Company does not have any other leases with a term exceeding twelve months. Other lease payments not accounted for under ASU Topic 842 total $0 and $14,392 for the three months ended March 31, 2022 and 2021, respectively. An ROU asset of $1,411,461 was recognized upon the CMI Transaction. The right of use assets and lease liabilities assumed from the CMI transaction were disposed of as part of the disposal of our discontinued operations, which is described in further detail above. The present value of the liabilities decreased by $0 and $132,230 for the three months ended March 31, 2022 and 2021, respectively. This balance is included in the operating section of the statement of cash flows for three months ended March 31, 2022 and 2021. Operating lease cost was approximately $0 and $ 159,5254 The Company does not have any leases that have not yet commenced which are significant. Legal Proceedings We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.	15. COMMITMENTS & CONTINGENCIES Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Lease Commitments The Company accounts for lease transactions in accordance with Topic 842, Leases There are no other leases that meet the reporting standards of ASU Topic 842 as the Company does not have any other leases with a term exceeding twelve months. Other lease payments not accounted for under ASU Topic 842 total $59,051 and $73,777 for the years ended December 31, 2021 and 2020, respectively. An ROU asset of $1,411,461 was recognized upon the CMI Transaction. The present value of the liabilities decreased by $519,671 and $472,154 for the years ended December 31, 2021 and 2020, respectively. This balance is included in the operating section of the statement of cash flows for the years ended December 31, 2021 and 2020. Operating lease cost was approximately $664,686 and $627,132 for the years ended December 31, 2021 and 2020, respectively. The right of use assets and lease liabilities assumed from the CMI transaction were disposed of as part of the disposal of our discontinued operations, which is described in further detail above. The Company does not have any leases that have not yet commenced which are significant. Legal Proceedings We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Subsequent to March 31, 2022, the Company issued 1,091,667 shares of common stock. 291,667 shares were issued at $0.35 per share in exchange for services, 800,000 shares were issued to three directors and one executive officer at $0.28 per share, and 200,000 shares were issued to an executive officer at $0.25 per share. Subsequent to March 31, 2022, the Company purchased property and equipment associated with testing of our processing equipment for a total value of $115,945. On April 5, 2022, the Company granted 500,000 shares for director services. The shares will vest on January 1, 2023.	16. SUBSEQUENT EVENTS On January 10, 2022, the Company’s shareholders approved a new stock incentive plan (the “2022 Stock Incentive Plan”). The purpose of the 2022 Stock Incentive Plan is to advance the interests of the Company and its stockholders by enabling the Company and its subsidiaries to attract and retain qualified individuals to perform services, to provide incentive compensation for such individuals in a form that is linked to the growth and profitability of the Company and increases in stockholder value, and to provide opportunities for equity participation that align the interests of recipients with those of its stockholders. Also on January 10, 2022, the Company’s shareholders approved an amendment to the Company’s Articles of Incorporation to effect a reverse stock split of the issued and outstanding shares of our Common Stock, par value $0.001 per share, such split to combine a whole number of outstanding shares of our Common Stock in a range of not less than three (3) shares and not more than ten (10) shares, into one share of Common Stock at any time prior to March 31, 2022. On January 12, 2022, the Company issued 735,529 shares of common stock to its three executive officers and 371,058 shares of common stock to two directors at a stock price of $0.27. On January 17, 2022, Mr. Simon Langelier was elected to the Company’s Board of Directors. Mr. Langelier holds a Bachelor of Science degree (Honors) in Management Sciences (Operational Research) from the University of Lancaster, United Kingdom. During his thirty-year career with Philip Morris International, until 2011, Mr. Langelier served in several senior positions, including President Eastern Europe, Middle East & Africa, President Eastern Asia and President of Next Generation Products & Adjacent Businesses. He was also Managing Director in numerous countries in Europe and Columbia. He is currently a director of Imperial Brands PLC. Mr. Langelier is also an Honorary Professorial Fellow at the University of Lancaster in the United Kingdom and a member of the Dean’s Council of that university’s Management School. Subsequent to year end, the Company has disbursed $620,000 in loans to CMI.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Cryomass Technologies Inc, Cryomass LLC, and CMI, a VIE for which the Company was deemed to be the primary beneficiary. All significant intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment from its corporate headquarters in Colorado. Effective December 31, 2021, the Company entered into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes all assets and liabilities from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power to direct activities, absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI.	Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Cryomass Technologies Inc, Cryomass LLC, and CMI, a VIE for which the Company was deemed to be the primary beneficiary. All significant intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment from its corporate headquarters in Colorado. Effective December 31, 2021, the Company entered into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes all assets and liabilities from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power to direct activities, absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the fair value and potential impairment of inventory, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.	Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the fair value and potential impairment of inventory, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain items in the consolidated financial statements were reclassified from prior periods for presentation purposes.	Reclassifications Certain items in the consolidated financial statements were reclassified from prior periods for presentation purposes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturities of three months or less at the time of issuance to be cash equivalents.	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturities of three months or less at the time of issuance to be cash equivalents.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable in conjunction with the disposal of discontinued operations at the end of 2021, which is backed by the assets of the discontinued operations, should the borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk.	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable in conjunction with the disposal of discontinued operations, which is backed by the assets of the discontinued operations, should the borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk.
Purchase Accounting for Acquisitions	Purchase Accounting for Acquisitions We apply the acquisition method of accounting for a business combination. In general, this methodology requires us to record assets acquired and liabilities assumed at their respective fair values at the date of acquisition. Any amount of the purchase price paid that is in excess of the estimated fair value of the net assets acquired is recorded as goodwill. For certain acquisitions, we also record a liability for contingent consideration based on estimated future business performance. We monitor our assumptions surrounding these estimated future cash flows and, if there is a significant change, would record an adjustment to the contingent consideration liability and a corresponding adjustment to either income or expense. We determine fair value using widely accepted valuation techniques, primarily discounted cash flow and market multiple analyses. These types of analyses require us to make assumptions and estimates regarding industry and economic factors, the profitability of future business strategies, discount rates and cash flow. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future. If the contingent consideration paid for any of our acquisitions differs from the amount initially recorded, we would record either income or expense associated with the change in liability.	Purchase Accounting for Acquisitions We apply the acquisition method of accounting for a business combination. In general, this methodology requires us to record assets acquired and liabilities assumed at their respective fair values at the date of acquisition. Any amount of the purchase price paid that is in excess of the estimated fair value of the net assets acquired is recorded as goodwill. For certain acquisitions, we also record a liability for contingent consideration based on estimated future business performance. We monitor our assumptions surrounding these estimated future cash flows and, if there is a significant change, would record an adjustment to the contingent consideration liability and a corresponding adjustment to either income or expense. We determine fair value using widely accepted valuation techniques, primarily discounted cash flow and market multiple analyses. These types of analyses require us to make assumptions and estimates regarding industry and economic factors, the profitability of future business strategies, discount rates and cash flow. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in the future. If the contingent consideration paid for any of our acquisitions differs from the amount initially recorded, we would record either income or expense associated with the change in liability.
Variable Interest Entities	Variable Interest Entities The Company accounts for variable interest entities in accordance with FASB ASC Topic 810, Consolidation	Variable Interest Entities The Company accounts for variable interest entities in accordance with FASB ASC Topic 810, Consolidation
Accounts Receivable, net	Accounts Receivable, net Accounts receivable, net is comprised of balances due from customers and are recorded at the invoiced amount. Past due balances are determined based on the contractual terms of the arrangements. Accounts receivable are accrued against when management determines, after considering economic and business conditions and all means of collection efforts have been exhausted and the potential for recovery is considered remote, that the collection of receivables is doubtful.	Accounts Receivable, net Accounts receivable, net is comprised of balances due from customers and are recorded at the invoiced amount. Past due balances are determined based on the contractual terms of the arrangements. Accounts receivable are accrued against when management determines, after considering economic and business conditions and all means of collection efforts have been exhausted and the potential for recovery is considered remote, that the collection of receivables is doubtful. Accounts receivable amounts, net of allowance for doubtful accounts, were $0 and $606,043 as of December 31, 2021 and 2020, respectively. This includes $0 and $66,043, respectively, related to the VIE. Uncollectible accounts previously recorded as receivables are recognized as bad debt expense, with a corresponding decrease to accounts receivable. Bad debt expense was $541,099 and $188,548 for the years ended December 31, 2021 and 2020, respectively. This amount includes $1,099 and $4,548, respectively, related to the VIE, which is classified as discontinued operations.
Inventory, net	Inventory, net Inventory, net is comprised of work-in-process and finished goods consisting of cannabis and cannabidiol products. Cost includes expenditures directly related to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Inventory, net is stated at the lower of cost or net realizable value. The Company compares the cost of inventory with market value and writes down inventories to net realizable value, if lower. In evaluating whether inventories are stated at lower of cost or net realizable value, management considers such factors as inventories on hand, physical deterioration, obsolescence, changes in price levels, estimated time to sell such inventories and current market conditions. Due to changing market conditions, management will periodically conduct a thorough review of its inventory and record a provision for inventory losses if necessary. This is based on the Company’s best estimates of product sales prices and customer demand patterns. It is at least reasonably possible that the estimates used by the Company to determine its provision for inventory losses will be materially different from the actual amounts or results. These differences could result in materially higher than expected inventory provisions, which could have a materially adverse effect on the Company’s results of operations and financial conditions in the near term.	Inventory, net Inventory, net is comprised of work-in-process and finished goods consisting of cannabis and cannabidiol products. Cost includes expenditures directly related to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Inventory, net is stated at the lower of cost or net realizable value. The Company compares the cost of inventory with market value and writes down inventories to net realizable value, if lower. In evaluating whether inventories are stated at lower of cost or net realizable value, management considers such factors as inventories on hand, physical deterioration, obsolescence, changes in price levels, estimated time to sell such inventories and current market conditions. Due to changing market conditions, management conducted a thorough review of its inventory. As a result, a provision for inventory losses of $0 and $400,787 was charged against cost of goods sold during the years ended December 31, 2021 and 2020, respectively, due to a write down of inventory to its net realizable value. This was based on the Company’s best estimates of product sales prices and customer demand patterns. It is at least reasonably possible that the estimates used by the Company to determine its provision for inventory losses will be materially different from the actual amounts or results. These differences could result in materially higher than expected inventory provisions, which could have a materially adverse effect on the Company’s results of operations and financial conditions in the near term.
Revenue Recognition	Revenue Recognition Under FASB Topic 606, Revenue from Contacts with Customers	Revenue Recognition Under FASB Topic 606, Revenue from Contacts with Customers
Discontinued Operations	Discontinued Operations For the three months ended March 31, 2021, Company’s revenue consisted of sales of cannabis and ancillary products to both retail consumers and wholesale customers. Revenue for retail customers was recognized upon completion of the transaction in the point of sale system and satisfaction of the sale by providing the corresponding inventory at the retail location. Revenue for wholesale customers was recognized upon acceptance of the physical goods and confirmation by acceptance of the inventory in the regulatory marijuana enforcement tracking reporting compliance (“METRC”) system. Revenue was recognized upon transfer of control of promised products to customers, generally as risk of loss passes, in an amount that reflected the consideration the Company expected to receive in exchange for those products. Taxes collected from customers, which was subsequently remitted to governmental authorities, were excluded from revenue. Retail customer loyalty liabilities were recognized in the period in which they were incurred and were often be retired without being utilized. Shipping and handling costs were expensed as incurred and are included in cost of sales. The Company operated in a highly regulated environment in which state regulatory approval was required prior to the customer being able to purchase the product, either through the Colorado Marijuana Enforcement Division for wholesale clients or the Colorado Department of Public Health and Environment for medical patients.	Discontinued Operations The Company’s revenue consists of sales of cannabis and ancillary products to both retail consumers and wholesale customers. Revenue for retail customers is recognized upon completion of the transaction in the point of sale system and satisfaction of the sale by providing the corresponding inventory at the retail location. Revenue for wholesale customers is recognized upon acceptance of the physical goods and confirmation by acceptance of the inventory in the regulatory marijuana enforcement tracking reporting compliance (“METRC”) system. Revenue is recognized upon transfer of control of promised products to customers, generally as risk of loss passes, in an amount that reflects the consideration the Company expects to receive in exchange for those products. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from revenue. Retail customer loyalty liabilities are recognized in the period in which they are incurred and will often be retired without being utilized. Shipping and handling costs are expensed as incurred and are included in cost of sales, which were not material for the years ended December 31, 2021 and 2020. The Company operates in a highly regulated environment in which state regulatory approval is required prior to the customer being able to purchase the product, either through the Colorado Marijuana Enforcement Division for wholesale clients or the Colorado Department of Public Health and Environment for medical patients.
Expenses	Expenses Operating Expenses Operating expenses encompass personnel costs, sales and marketing expenses, research and development expenses, general and administrative expenses, professional and legal fees and depreciation and amortization related to the property and equipment and intangibles acquired through the acquisition of CMI and Cryocann. Personnel costs consist primarily of consulting expense and administrative salaries and wages. Sales and marketing expenses consist primarily of advertising and marketing, and salaries related to sales and marketing employees. General and administrative expenses are comprised of travel expenses, accounting expenses, and board fees. Professional services are principally comprised of outside legal and professional fees. Discontinued Operations Cost of Goods Sold, Net of Depreciation and Amortization Cost of goods sold primarily consisted of allocated salaries and wages of employees directly related with the production process, allocated depreciation and amortization directly related to the production process, cultivation supplies, rent and utilities. Other Expense, net Other expense, net consisted of interest expense, other income and (loss) gain on foreign exchange.	Expenses Operating Expenses Operating expenses encompass personnel costs, sales and marketing expenses, general and administrative expenses, professional and legal fees and depreciation and amortization related to the property and equipment and intangibles acquired through the acquisition of CMI and Cryocann. Personnel costs consist primarily of consulting expense and administrative salaries and wages. Sales and marketing expenses consist primarily of advertising and marketing, and salaries related to sales and marketing employees. General and administrative expenses are comprised of travel expenses, accounting expenses, and board fees. Professional services are principally comprised of outside legal and professional fees. Discontinued Operations Cost of Goods Sold, Net of Depreciation and Amortization Cost of goods sold primarily consisted of allocated salaries and wages of employees directly related with the production process, allocated depreciation and amortization directly related to the production process, cultivation supplies, rent and utilities. Other Expense, net Other expense, net consisted of interest expense, other income and (loss) gain on foreign exchange.
Stock-Based Compensation	Stock-Based Compensation The fair value of restricted stock units (“RSUs”) granted are measured on the grant date using the closing price of the Company’s common shares on the grant date. For stock options, the Company engages a valuation firm to calculate the grant date fair value of the options issued. The Company accounts for forfeitures as they occur, rather than estimating expected forfeitures over the course of a vesting period. All stock-based compensation costs are recorded in general and administrative expenses in the consolidated statements of operations.	Stock-Based Compensation The fair value of restricted stock units (“RSUs”) granted are measured on the grant date using the closing price of the Company’s common shares on the grant date. For stock options, the Company engages a valuation firm to calculate the grant date fair value of the options issued. The Company accounts for forfeitures as they occur, rather than estimating expected forfeitures over the course of a vesting period. All stock-based compensation costs are recorded in general and administrative expenses in the consolidated statements of operations.
Property and Equipment, net	Property and Equipment, net Purchase of property and equipment are recorded at cost. Improvements and replacements of property and equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the consolidated statements of operations. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Computer equipment 3 – 5 years Furniture and fixtures 5 – 7 years Machinery and equipment 5 – 8 years Leasehold improvements Shorter of lease term	Property and Equipment, net Purchase of property and equipment are recorded at cost. Improvements and replacements of property and equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the consolidated statements of operations. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Useful Life Computer equipment 3 – 5 years Furniture and fixtures 5 – 7 years Machinery and equipment 5 – 8 years Leasehold improvements Shorter of lease term or 15 years
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of an acquired entity over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. Indefinite-lived intangible assets established in connection with business combinations consists of in process research and development. Intangible assets with indefinite lives are recorded at their estimated fair value at the date of acquisition. Once in process research and development is placed in service, it will be amortized over the estimated useful life. Intangible assets with finite lives are recorded at their estimated fair value at the date of acquisition and are amortized over their estimated useful lives using the straight-line method. Amortization of assets ceases upon designation as held for sale. The estimated useful lives of intangible assets are detailed in the table below: Estimated Patent 10 years In process research and development Indefinite	Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of an acquired entity over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. Indefinite-lived intangible assets established in connection with business combinations consists of in process research and development. Intangible assets with indefinite lives are recorded at their estimated fair value at the date of acquisition. Once in process research and development is placed in service, it will be amortized over the estimated useful life. Intangible assets with finite lives are recorded at their estimated fair value at the date of acquisition and are amortized over their estimated useful lives using the straight-line method. Amortization of assets ceases upon designation as held for sale. The estimated useful lives of intangible assets are detailed in the table below: Estimated Useful Life Patent 10 years In process research and development Indefinite
Impairment of Goodwill and Intangible Assets	Impairment of Goodwill and Intangible Assets Goodwill Goodwill is not amortized, but instead is tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of goodwill under the provisions of Financial Accounting Standards Board (FASB) Accounting Standard Update 2017-04 (“ASU 2017-04”), “ Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Intangibles – Goodwill and Other – Goodwill The Company performs impairment testing for goodwill by performing the following steps: 1) evaluate the relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, 2) if yes to step 1, calculate the fair value of the reporting unit and compare it with its carrying amount, including goodwill, 3) recognize impairment, limited to the total amount of goodwill allocated to that reporting unit, equal to the excess of the carrying value of a reporting unit over its fair value. Management concluded that there were no events indicative of goodwill impairment during the three months ended March 31, 2022.	Impairment of Goodwill and Intangible Assets Goodwill Goodwill is not amortized, but instead is tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of goodwill under the provisions of Financial Accounting Standards Board (FASB) Accounting Standard Update 2017-04 (“ASU 2017-04”), “ Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Intangibles – Goodwill and Other – Goodwill The Company performs impairment testing for goodwill by performing the following steps: 1) evaluate the relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, 2) if yes to step 1, calculate the fair value of the reporting unit and compare it with its carrying amount, including goodwill, 3) recognize impairment, limited to the total amount of goodwill allocated to that reporting unit, equal to the excess of the carrying value of a reporting unit over its fair value. During the year ended December 31, 2020, the Company concluded that goodwill resulting from the CMI transaction was impaired, resulting in a $4,663,514 impairment charge included in net loss from discontinued operations. In accordance with ASC 350, as of December 31, 2021, management concluded that the goodwill resulting from the Cryocann acquisition was not impaired.
Indefinite-Lived Intangible Assets and Intangible Assets Subject to Amortization	Indefinite-Lived Intangible Assets and Intangible Assets Subject to Amortization Indefinite-lived intangible assets and intangible assets subject to amortization are not amortized, but instead are tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of indefinite-lived intangible assets under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35, Intangibles – Goodwill and Other – General Intangibles Other Than Goodwill We account for the impairment of intangible assets subject to amortization under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Property, Plant, and Equipment Management concluded that there were no events indicative of identifiable intangible asset impairment during the three months ended March 31, 2022.	Indefinite-Lived Intangible Assets and Intangible Assets Subject to Amortization Indefinite-lived intangible assets and intangible assets subject to amortization are not amortized, but instead are tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances. We account for the impairment of indefinite-lived intangible assets under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35, Intangibles – Goodwill and Other – General Intangibles Other Than Goodwill We account for the impairment of intangible assets subject to amortization under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Property, Plant, and Equipment During the year ended December 31, 2020, the Company concluded that intangible assets resulting from the CMI transaction were impaired, resulting in an impairment charge of $316,218, which is included in net loss from discontinued operations. As of December 31, 2021, management concluded that identifiable intangible assets resulting from the Cryocann transaction were not impaired.
Contingencies		Contingencies An initial right-of-use (“ROU”) asset and corresponding liability of $1,411,461 was recognized upon the CMI Transaction. The Company adopted ASU Topic 842 January 1, 2019, but had no reportable operating leases at that point in time. As of December 31, 2021, our ROU assets and liabilities associated with CMI were no longer included on the consolidated balance sheets.
Income Taxes	Income Taxes The Company uses the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes	Income Taxes The Company uses the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes
Fair Value Measurements	Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values reported in the consolidated balance sheets for cash, prepaid expenses, inventories, accounts payable, and notes payable approximate fair values because of the immediate or short-term maturities of these financial instruments. There were no other assets or liabilities that require fair value to be recalculated on a recurring basis. The fair value of beneficial conversion features associated with convertible notes and the fair value of warrants are calculated utilizing level 2 inputs. When multiple instruments are issued in a single transaction, the total proceeds from the transaction should be allocated among the individual freestanding instruments identified. The allocation occurs after identifying (1) all the freestanding instruments and (2) the subsequent measurement basis for those instruments. The subsequent measurement basis helps inform how the proceeds should be allocated. After the proceeds are allocated to the freestanding instruments, those instruments should be further evaluated for embedded features that may need to be bifurcated or separated. If debt or stock is issued with detachable warrants, the guidance in ASC 470-20-25-2 (applied by analogy to stock) requires that the proceeds be allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt or stock is issued with any other freestanding instrument that is classified in equity (such as a detachable forward contract) or as a liability but not subject to subsequent fair value accounting. Given that our convertible notes and common stock that were issued with warrants are both not subject to subsequent fair value accounting treatment, Management determined the relative fair value method shall be used for allocating the proceeds of the transaction. Under the relative fair value method, the instrument being analyzed is allocated a portion of the proceeds based on its fair value to the sum of the fair value of all the instruments covered int the allocation. Management additionally evaluates the facts and circumstances to determine whether the principal balance of convertible notes approximate their fair value, which we have concluded for all convertible notes issued.	Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values reported in the consolidated balance sheets for cash, prepaid expenses, inventories, accounts payable, notes payable, and taxes payable approximate fair values because of the immediate or short-term maturities of these financial instruments. There were no other assets or liabilities that require fair value to be recalculated on a recurring basis. The fair value of beneficial conversion features associated with convertible notes and the fair value of warrants are calculated utilizing level 2 inputs. When multiple instruments are issued in a single transaction, the total proceeds from the transaction should be allocated among the individual freestanding instruments identified. In this case, there were warrants issued in conjunction with convertible notes of $4.9 million and $250K and the sale of common stock through subscription agreements for $679K and $10.3 million. The allocation occurs after identifying (1) all the freestanding instruments and (2) the subsequent measurement basis for those instruments. The subsequent measurement basis helps inform how the proceeds should be allocated. After the proceeds are allocated to the freestanding instruments, those instruments should be further evaluated for embedded features that may need to be bifurcated or separated. If debt or stock is issued with detachable warrants, the guidance in ASC 470-20-25-2 (applied by analogy to stock) requires that the proceeds be allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt or stock is issued with any other freestanding instrument that is classified in equity (such as a detachable forward contract) or as a liability but not subject to subsequent fair value accounting. Given that the convertible notes and common stock that were issued with warrants are both not subject to subsequent fair value accounting treatment, Management determined the relative fair value method shall be used for allocating the proceeds of the transaction. Under the relative fair value method, the instrument being analyzed is allocated a portion of the proceeds based on its fair value to the sum of the fair value of all the instruments covered int the allocation. Management additionally evaluated the facts and circumstances to determine whether the principal balance of the Notes ($4.9 million and $250K) approximated their fair value. The Notes were issued entirely to unrelated third parties which were deemed to be arm’s length transactions. In addition, the comparable interest rates for loans of similar companies as of the date of the Note issuances range from 10-15% given the liquidity concerns of the Company. The term of the Notes issued range from 8-15 months, which would support the conclusion that the principal balance approximates their fair value given the short-term maturities of each Note. Finally, the Warrants issued in connection with the Notes were included akin to a “sweetener” in the offering as opposed to compensation for adjusting the interest rate or other key terms within the Convertible Term Loan Agreements. As such, the Company concluded that the principal balance of the Notes approximated their fair value. The Warrants were initially measured at fair value and subsequent fair value measurement is not required as long as the instrument continues to be classified in equity. The proceeds from each transaction were allocated between the Notes and Warrants as well as common stock and Warrants based on the relative fair value method. Warrants issued in connection with cash provided for common shares, and not convertible notes, during the fourth quarter of 2021 also followed the same fair value assessment and treatment as noted above.
Net Loss per Share	Net Loss per Share The Company follows ASC 260, Earnings Per Share	Net Loss per Share The Company follows ASC 260, Earnings Per Share
Assets and Liabilities of Discontinued Operations Held for Sale		Assets and Liabilities of Discontinued Operations Held for Sale Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets (and liabilities) are classified as held for sale in the balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation of assets ceases upon designation as held for sale.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40).	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (ASC 350), In February 2016, the FASB issued ASU No. 2016-02, Leases

Variable Interest Entity (Table

Variable Interest Entity (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Schedule of CMI assets and liabilities		CMI Assets & Liabilities As of December 31, Description 2021 2020 Current assets Cash and cash equivalents $ - $ 196,445 Accounts receivable, net - 66,043 Inventory, net - 791,868 Total current assets - 1,054,356 Total assets $ - $ 1,054,356 Current liabilities Accounts payable and accrued expenses $ - $ 211,463 Total current liabilities - 211,463 Total liabilities - 211,463 Net assets $ - $ 842,893
Schedule of CMI statement of operations	CMI Statement of Operations For the Three Months Ended Description 2022 2021 Net sales $ - $ 1,695,925 Cost of goods sold, inclusive of depreciation - 1,118,735 Gross profit $ - $ 577,190 Operating expenses Personnel costs - 154,460 Sales and marketing - 226,347 General and administrative - 28,988 Legal and professional fees - 21,515 Total operating expenses - 431,310 Gain from operations $ - $ 145,880 Other income / (expense) Interest expense - (29,264 ) Total other income / (expense) - (29,264 ) Net loss - 116,616	CMI Statement of Operations For the Years Ended Description 2021 2020 Net sales $ 5,891,894 $ 6,860,282 Cost of goods sold, inclusive of depreciation 4,132,696 4,901,237 Gross profit $ 1,759,198 $ 1,959,045 Operating expenses Personnel costs 428,728 402,389 Sales and marketing 816,683 908,502 General and administrative 112,934 231,376 Legal and professional fees 44,092 156,782 Amortization expense - 26,901 Total operating expenses 1,402,437 1,725,950 Gain from operations $ 356,761 $ 233,095 Other income / (expense) Interest expense (49,803 ) (153,592 ) Goodwill impairment - (4,663,514 ) Intangibles impairment - (361,218 Other income - - Total other income / (expense) (49,803 ) (5,178,324 ) Loss on disposal of discontinued operations (3,021,724 ) - Net income / (loss), before taxes (2,714,766 ) (4,945,229 ) Income taxes (10,235 ) (10,235 ) Net income / (loss), net of taxes $ (2,725,001 ) $ (4,955,464 )

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of estimated useful life of property and equipment	Estimated Computer equipment 3 – 5 years Furniture and fixtures 5 – 7 years Machinery and equipment 5 – 8 years Leasehold improvements Shorter of lease term	Estimated Useful Life Computer equipment 3 – 5 years Furniture and fixtures 5 – 7 years Machinery and equipment 5 – 8 years Leasehold improvements Shorter of lease term or 15 years
Schedule of estimated useful lives of intangible assets	Estimated Patent 10 years In process research and development Indefinite	Estimated Useful Life Patent 10 years In process research and development Indefinite

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue	For the Three Months Ended 2022 2021 Types of Revenues: Medical retail $ - $ 1,130,504 Medical wholesale - 556,310 Recreational wholesale - 9,010 Total revenues $ - $ 1,130,504	For the Years Ended 2021 2020 Types of Revenues: Medical retail $ - $ 11,200 Medical wholesale - 700 Recreational wholesale - 769,555 Total revenues $ - $ 781,455

Business Combination (Tables)

Business Combination (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Business Combinations [Abstract]
Schedule of purchase price	Cash $ 2,247,684 Common stock 1,804,500 Promissory Note 1,220,079 Total purchase price $ 5,272,263	Cash $ 2,247,684 Common stock 1,804,500 Promissory Note 1,220,079 Total purchase price $ 5,272,263
Schedule of business combination	Description Fair Value Weighted Assets acquired: Intangible assets: In process research and development 3,209,000 Indefinite Patent 873,263 10 Goodwill 1,190,000 Total assets acquired $ 5,272,263	Description Fair Value Weighted Assets acquired: Intangible assets: In process research and development 3,209,000 Indefinite Patent 873,263 10 Goodwill 1,190,000 Total assets acquired $ 5,272,263
Schedule of pro forma financial information		For the Years Ended 2022 2021 Net Sales $ 7,641,737 $ 7,641,737 Net loss $ (12,417,483 ) $ (12,417,483 ) Net loss per common share $ (0.08 ) $ (0.08 )

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of assets and liabilities related to these CMI discontinued operations		December 31, December 31, Assets Accounts receivable, net $ - $ 66,043 Prepaid expenses - 7,601 Inventory, net - 791,868 Property and equipment, net - 2,714,771 Goodwill - - Intangible assets, net - 2,481,128 Security deposits - 11,522 Right of use asset, net - 794,907 Total current assets held for sale - 6,867,840 Total assets held for sale $ - $ 6,867,840 Liabilities Accounts payable and accrued expenses - 211,463 Taxes payable - 22,645 Notes payable, related parties - 458,599 Right of use liability - 771,578 Total liabilities held for sale - 1,464,285 Net assets $ - $ 5,403,555
Schedule of discontinued operations statements of operations	Three Months Ended 2022 2021 Net sales $ - $ 1,695,925 Cost of goods sold, inclusive of depreciation - 1,118,735 Gross profit - 577,190 Operating expenses: Personnel costs - 154,460 Sales and marketing - 226,347 General and administrative - 28,988 Legal and professional fees - 21,515 Total operating expenses - 431,310 Gain / (loss) from operations - 145,880 Other income (expenses): Interest expense - (29,264 ) Total other expenses - (29,264 ) Net gain / (loss) from discontinued operations, before taxes - 116,616 Income taxes - - Net gain / (loss) from discontinued operations $ - $ 116,616	Year Ended 2021 2020 Net sales $ 5,891,894 $ 6,860,282 Cost of goods sold, inclusive of depreciation 4,132,696 4,901,237 Gross profit 1,759,198 1,959,045 Operating expenses: Personnel costs 428,728 402,389 Sales and marketing 816,683 908,502 General and administrative 112,934 231,376 Legal and professional fees 44,092 156,782 Amortization expense - 26,901 Total operating expenses 1,402,437 1,725,950 Gain from operations 356,761 233,095 Other income (expenses): Interest expense (49,803 ) (153,592 ) Goodwill impairment - (4,663,514 ) Intangibles impairment - (361,218 ) Other income - - Total other income (expenses) (49,803 ) (5,178,324 ) Loss on disposal of discontinued operations (3,021,724 ) (4,945,229 ) Net gain / (loss) from discontinued operations, before taxes (2,714,766 ) (4,945,229 ) Income taxes (10,235 ) (10,235 ) Net gain / (loss) from discontinued operations $ (2,725,001 ) $ (4,955,464 )

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	March 31, December 31, Leasehold improvements $ - $ - Machinery and equipment 233,641 225,000 Furniture and fixtures - - Construction in progress - - 233,641 225,000 Less: Accumulated depreciation - - $ 233,641 $ 225,000	December 31, December 31, Leasehold improvements $ - $ 2,770,385 Machinery and equipment 225,000 1,065,885 Furniture and fixtures - 43,331 Construction in progress - 227,995 225,000 4,107,596 Less: Accumulated depreciation - (1,392,825 ) $ 225,000 $ 2,714,771

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of identifiable intangible assets	March 31, 2022 Estimated Gross Accumulated Carrying Amortized Patent 10 years $ 873,263 $ (65,495 ) $ 807,768 Indefinite-lived In-process research and development Indefinite 3,209,000 - 3,209,000 Total identifiable intangible assets $ 4,082,263 $ (65,495 ) $ 4,016,768 December 31, 2021 Estimated Gross Accumulated Carrying Amortized Patent 10 years $ 873,263 $ (43,663 ) $ 829,600 Indefinite-lived In-process research and development Indefinite 3,209,000 - 3,209,000 Total identifiable intangible assets $ 4,082,263 $ (43,663 ) $ 4,038,600	Estimated Gross Accumulated Amortization Carrying Amortized Patent 10 years 873,263 (43,663 ) 829,600 Indefinite-lived In-process research and development Indefinite 3,209,000 - 3,209,000 Total identifiable intangible assets $ 4,082,263 $ (43,663 ) $ 4,038,600

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of the company's RSU award activity	Restricted Weighted Outstanding at December 31, 2021 2,200,003 $ 0.45 Granted 1,469,511 0.27 Vested (1,735,529 ) 0.49 Forfeited - - Outstanding at March 31, 2022 1,933,982 $ 0.27	Restricted Stock Weighted Outstanding at December 31, 2020 2,453,175 $ 0.45 Granted 6,650,000 0.15 Vested (6,903,172 ) 0.15 Forfeited - - Outstanding at December 31, 2021 2,200,003 $ 0.45
Schedule of stock options activity	Stock Weighted Weighted Aggregate Outstanding at December 31, 2021 8,500,000 $ 0.18 9.2 $ 1,579,108 Granted and vested - - - - Forfeited - - - - Outstanding at March 31, 2022 8,500,000 $ 0.18 9.0 $ 1,579,108	Stock Weighted Weighted Aggregate Outstanding at December 31, 2020 3,500,000 $ 0.16 8.8 $ 581,591 Granted and vested 5,000,000 0.20 9.5 987,517 Forfeited - - - - Outstanding at December 31, 2021 8,500,000 $ 0.18 9.2 $ 1,579,108

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of provision (benefit) for income taxes	2021 2020 Current (benefit) provision Federal $ - $ - State - - Total Current - - Deferred (benefit) provision Federal $ 3,724 $ 3,724 State 6,511 6,511 Total Deferred $ 10,235 $ 10,235 Total Provision $ 10,235 $ 10,235
Schedule of statutory federal income tax rate	2021 2020 Tax Percentage Tax Percentage Income Taxes At Statutory Federal Income Tax Rate $ (2,202,256 ) 21.00 % $ (2,517,221 ) 21.00 % State Taxes, Net Of Federal Income Tax Benefit 6,511 (0.06 ) 6,511 (0.05 ) Meals & Entertainment - 0.00 261 0.00 ) Penalties and Fines - 0.00 - 0.00 Return to Provision Adjustment - Permanent Items - 0.00 - 0.00 Deferred Only Adjustment - 0.00 (228,539 ) 1.91 Change in Valuation Allowance 1,838,803 (17.53 ) 200,791 (1.68 ) Section 280E Expense Disallowance 367,177 (3.50 ) 2,548,431 (21.26 ) Other - 0.00 - 0.00 Effective tax $ 10,235 (0.10 )% $ 10,235 (0.09 )%
Schedule of deferred tax assets and liabilities	Deferred Tax Assets (Liabilities): 2021 2020 Stock Compensation $ (7,335 ) $ 62,606 Stock Compensation - Options 259,057 - Accrued Salary 44,384 - Trademark/Trade Name (8,033 ) (4,765 ) Developed Manufacturing Process - Extraction (53,747 ) (31,884 ) Customer Relationships 1,947 1,158 Patent 3,589 - In-Process Research & Development - CryoCann (26,376 ) - Goodwill - CMI 179,892 168,688 In-Process Research & Development - CMI 98,135 105,985 Goodwill - CryoCann 3,490 - NOL - Federal Pre-2018 43,367 43,367 NOL - Federal Post-2017 2,097,542 377,529 NOL - State 608,703 294,183 Deferred Tax Assets (Liabilities) $ 3,244,615 $ 1,016,867 Valuation Allowance (3,269,776 ) (1,031,792 ) Net Deferred Tax Assets (Liabilities) $ (25,160 ) $ (14,926 )

Nature of the Business (Details

Nature of the Business (Details) - USD ($)	Jul. 15, 2019	Nov. 17, 2021	Jun. 22, 2021	Dec. 31, 2021	Jul. 01, 2019
Nature of the Business (Details) [Line Items]
Membership interests acquired				10.00%
Denver, CO, operates square-foot, description				Good Meds, the operating unit of CMI, is based in Denver, CO, and operates in a 60,000-square-foot cultivation and processing facility.
Aggregate purchase price			$ 3,500,000,000,000
Common stock shares			10,000,000
Medical cannabis				$ 6,000,000,000
Equity financing cost		$ 10,300,000
Purchase share issued		1,010,000
Chief Executive Officer [Member]
Nature of the Business (Details) [Line Items]
Purchase share issued		760,000
General Extract, LLC [Member]
Nature of the Business (Details) [Line Items]
Membership interests acquired					100.00%
Critical Mass Industries [Member]
Nature of the Business (Details) [Line Items]
Cash paid	$ 1,999,770
Critical Mass Industries [Member] | First Colombia Devco S.A.S [Member]
Nature of the Business (Details) [Line Items]
Shares issued	13,553,233

Variable Interest Entity (Detai

Variable Interest Entity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Promissory note due	$ 3,600,000
Loss on disposal of discontinued operations	$ 3,021,724	$ 3,021,724
Due date	Dec. 31, 2023

Variable Interest Entity (Det_2

Variable Interest Entity (Details) - Schedule of CMI assets and liabilities - VIE's [Member] - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents		$ 196,445
Accounts receivable, net		66,043
Inventory, net		791,868
Total current assets		1,054,356
Total assets		1,054,356
Current liabilities
Accounts payable and accrued expenses		211,463
Total current liabilities		211,463
Total liabilities		211,463
Net assets		$ 842,893

Variable Interest Entity (Det_3

Variable Interest Entity (Details) - Schedule of CMI statement of operations - VIE's [Member] - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity (Details) - Schedule of CMI statement of operations [Line Items]
Net sales		$ 1,695,925	$ 5,891,894	$ 6,860,282
Cost of goods sold, inclusive of depreciation		1,118,735	4,132,696	4,901,237
Gross profit		577,190	1,759,198	1,959,045
Operating expenses
Personnel costs		154,460	428,728	402,389
Sales and marketing		226,347	816,683	908,502
General and administrative		28,988	112,934	231,376
Legal and professional fees		21,515	44,092	156,782
Amortization expense				26,901
Total operating expenses		431,310	1,402,437	1,725,950
Gain from operations		145,880	356,761	233,095
Other income / (expense)
Interest expense		(29,264)	(49,803)	(153,592)
Goodwill impairment				(4,663,514)
Intangibles impairment				361,218
Other income
Total other income / (expense)		(29,264)	(49,803)	(5,178,324)
Loss on disposal of discontinued operations			(3,021,724)
Net income / (loss), before taxes			(2,714,766)	(4,945,229)
Income taxes			(10,235)	(10,235)
Net income / (loss), net of taxes		$ 116,616	$ (2,725,001)	$ (4,955,464)

Going Concern Uncertainty, Fi_2

Going Concern Uncertainty, Financial Conditions and Management’s Plans (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Going Concern Uncertainty, Financial Conditions and Management’s Plans (Details) [Line Items]
Raised common stock amount		$ 110,000	$ 10,308,000	$ 537,850
Convertible notes			4,900,000
Cash for operating activities	(1,631,300)	(466,223)	(5,600,512)	(3,749,621)
Net loss	(2,152,305)	(1,046,927)	(12,859,643)	(11,815,907)
Accumulated deficit	30,741,142		28,588,837
Incurred net loss	2,152,305
Common Stock [Member]
Going Concern Uncertainty, Financial Conditions and Management’s Plans (Details) [Line Items]
Raised common stock amount			10,548,535
Net loss

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Loans receivable		$ 3,600,000	$ 3,600,000
Allowance for doubtful accounts			0	$ 606,043
Decrease to accounts receivable				540,000
Bad debt expense			541,099	188,548
Provision for inventory loss			$ 0	400,787
Impairment charge				$ 4,663,514
Income taxes, description	In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the financial statements.		In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the financial statements.
Fair value measurements, description			When multiple instruments are issued in a single transaction, the total proceeds from the transaction should be allocated among the individual freestanding instruments identified. In this case, there were warrants issued in conjunction with convertible notes of $4.9 million and $250K and the sale of common stock through subscription agreements for $679K and $10.3 million. The allocation occurs after identifying (1) all the freestanding instruments and (2) the subsequent measurement basis for those instruments. The subsequent measurement basis helps inform how the proceeds should be allocated. After the proceeds are allocated to the freestanding instruments, those instruments should be further evaluated for embedded features that may need to be bifurcated or separated. If debt or stock is issued with detachable warrants, the guidance in ASC 470-20-25-2 (applied by analogy to stock) requires that the proceeds be allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt or stock is issued with any other freestanding instrument that is classified in equity (such as a detachable forward contract) or as a liability but not subject to subsequent fair value accounting. Given that the convertible notes and common stock that were issued with warrants are both not subject to subsequent fair value accounting treatment, Management determined the relative fair value method shall be used for allocating the proceeds of the transaction. Under the relative fair value method, the instrument being analyzed is allocated a portion of the proceeds based on its fair value to the sum of the fair value of all the instruments covered int the allocation. Management additionally evaluated the facts and circumstances to determine whether the principal balance of the Notes ($4.9 million and $250K) approximated their fair value. The Notes were issued entirely to unrelated third parties which were deemed to be arm’s length transactions. In addition, the comparable interest rates for loans of similar companies as of the date of the Note issuances range from 10-15% given the liquidity concerns of the Company. The term of the Notes issued range from 8-15 months, which would support the conclusion that the principal balance approximates their fair value given the short-term maturities of each Note.
Potentially dilutive securities outstanding (in Shares)	1,933,982	2,050,000
Restricted Stock Units (RSUs) [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Potentially dilutive securities outstanding (in Shares)			2,200,003	2,453,172
Variable Interest Entity, Primary Beneficiary [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Decrease to accounts receivable			$ 0	$ 66,043
Bad debt expense			1,099	4,548
CMI Transaction [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Impairment charge				$ 316,218
Right-of-use assets and corresponding liability			$ 1,411,461

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Computer equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	3 years	3 years
Computer equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Furniture and fixtures [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Furniture and fixtures [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	7 years	7 years
Machinery and equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Machinery and equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	8 years	8 years
Leasehold improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	15 years	15 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of intangible assets	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of estimated useful lives of intangible assets [Abstract]
Patent	10 years	10 years
In process research and development	Indefinite	Indefinite

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of disaggregated revenue - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenues		$ 1,130,504		$ 781,455
Medical retail [Member]
Disaggregation of Revenue [Line Items]
Total revenues		1,130,504		11,200
Medical wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenues		556,310		700
Recreational wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenues		$ 9,010		$ 769,555

Business Combination (Details)

Business Combination (Details) - USD ($)	Oct. 15, 2021	Oct. 15, 2021	Jun. 23, 2021	Jun. 22, 2021	Jan. 01, 2021	Mar. 31, 2021	Apr. 23, 2021
Business Combination (Details) [Line Items]
Aggregate purchase price		$ 1,000,000		$ 3,500,000,000,000
Shares of common stock (in Shares)		10,000,000		10,000,000
Promissory note issued	$ 1,252,316
Purchase price							$ 2,500,000
Net loss					$ 2,025,847
Net loss per share (in Dollars per share)						$ 0.02
Cryocann [Member]
Business Combination (Details) [Line Items]
Aggregate purchase price			$ 3,500,000,000,000
Shares of common stock (in Shares)			10,000,000
Promissory note issued		$ 1,252,316
Purchase price							$ 2,500,000

Business Combination (Details)

Business Combination (Details) - Schedule of purchase price - Cryocann Acquisition [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Business Combination (Details) - Schedule of purchase price [Line Items]
Cash	$ 2,247,684	$ 2,247,684
Common stock	1,804,500	1,804,500
Promissory Note		1,220,079
Total purchase price	$ 5,272,263	$ 5,272,263

Business Combination (Details_2

Business Combination (Details) - Schedule of business combination - Cryocann Acquisition [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible assets:
In process research and development, Fair Value	$ 3,209,000	$ 3,209,000
In process research and development, Weighted average useful life (in years)	Indefinite	Indefinite
Patent, Fair Value	$ 873,263	$ 873,263
Patent, Weighted average useful life (in years)	10 years	10 years
Goodwill, Fair Value	$ 1,190,000	$ 1,190,000
Total assets acquired, Fair Value	$ 5,272,263	$ 5,272,263

Business Combination (Details_3

Business Combination (Details) - Schedule of pro forma financial information - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of pro forma financial information [Abstract]
Net Sales	$ 7,641,737	$ 7,641,737
Net loss	$ (12,417,483)	$ (12,417,483)
Net loss per common share (in Dollars per share)	$ (0.08)	$ (0.08)

Discontinued Operations (Detail

Discontinued Operations (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
CMI Transaction [Member]
Discontinued Operations (Details) [Line Items]
Loss on disposal of discontinued operations	$ 3,021,724

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of assets and liabilities related to these CMI discontinued operations - CMI Transaction [Member] - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Assets
Accounts receivable, net		$ 66,043
Prepaid expenses		7,601
Inventory, net		791,868
Property and equipment, net		2,714,771
Goodwill
Intangible assets, net		2,481,128
Security deposits		11,522
Right of use asset, net		794,907
Total current assets held for sale		6,867,840
Total assets held for sale		6,867,840
Liabilities
Accounts payable and accrued expenses		211,463
Taxes payable		22,645
Notes payable, related parties		458,599
Right of use liability		771,578
Total liabilities held for sale		1,464,285
Net assets		$ 5,403,555

Discontinued Operations (Deta_3

Discontinued Operations (Details) - Schedule of discontinued operations statements of operations - CMI Transaction [Member] - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Discontinued Operations (Details) - Schedule of discontinued operations statements of operations [Line Items]
Net sales		$ 1,695,925	$ 5,891,894	$ 6,860,282
Cost of goods sold, inclusive of depreciation		1,118,735	4,132,696	4,901,237
Gross profit		577,190	1,759,198	1,959,045
Operating expenses:
Personnel costs		154,460	428,728	402,389
Sales and marketing		226,347	816,683	908,502
General and administrative		28,988	112,934	231,376
Legal and professional fees		21,515	44,092	156,782
Amortization expense				26,901
Total operating expenses		431,310	1,402,437	1,725,950
Gain from operations		145,880	356,761	233,095
Other income (expenses):
Interest expense		(29,264)	(49,803)	(153,592)
Goodwill impairment				(4,663,514)
Intangibles impairment				(361,218)
Other income
Total other income (expenses)		(29,264)	(49,803)	(5,178,324)
Loss on disposal of discontinued operations			(3,021,724)	(4,945,229)
Net gain / (loss) from discontinued operations, before taxes		116,616	(2,714,766)	(4,945,229)
Income taxes			(10,235)	(10,235)
Net gain / (loss) from discontinued operations		$ 116,616	$ (2,725,001)	$ (4,955,464)

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 131,110

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 233,641	$ 225,000	$ 4,107,596
Less: Accumulated depreciation			(1,392,825)
Property and equipment, net	233,641	225,000	2,714,771
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross			2,770,385
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	233,641	225,000	1,065,885
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross			43,331
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross			$ 227,995

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying value of goodwill	$ 1,190,000		$ 1,190,000	$ 0
Amortization expense	$ 21,832	$ 0	$ 43,663	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details) - Schedule of identifiable intangible assets - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Indefinite-lived
Indefinite-lived Intangible assets, Gross Amount	$ 4,082,263	$ 4,082,263	$ 4,082,263
Indefinite-lived Intangible assets, Accumulated Amortization	(65,495)	(43,663)	(43,663)
Indefinite-lived intangible assets, Carrying Value	$ 4,016,768	$ 4,038,600	$ 4,038,600
Patent [Member]
Amortized
Amortized intangible assets, Estimated Useful Life (Years)	10 years	10 years	10 years
Amortized intangible assets, Gross Amount	$ 873,263	$ 873,263	$ 873,263
Amortized intangible assets, Accumulated Amortization	(65,495)	(43,663)	(43,663)
Amortized intangible assets, Carrying Value	$ 807,768	$ 829,600	$ 829,600
In-process research and development [Member]
Indefinite-lived
Indefinite-lived intangible assets, Estimated Useful Life (Years)	Indefinite	Indefinite	Indefinite
Indefinite-lived Intangible assets, Gross Amount	$ 3,209,000	$ 3,209,000	$ 3,209,000
Indefinite-lived Intangible assets, Accumulated Amortization
Indefinite-lived intangible assets, Carrying Value	$ 3,209,000	$ 3,209,000	$ 3,209,000

Loan Receivable (Details)

Loan Receivable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Loan Receivable [Abstract]
Promissory note due		$ 3,600,000
Additional loans	$ 620,000

Debt (Details)

Debt (Details) - USD ($)	Aug. 20, 2021	Mar. 18, 2021	Jan. 25, 2021	Jul. 27, 2020	Jul. 06, 2021	Jul. 06, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Aug. 26, 2020
Debt (Details) [Line Items]
Interest per annum		15.00%			12.00%	12.00%
Net carrying amount									$ 208,333
Convertible notes							$ 4,900,000		250,000
Unamortized debt discount									$ 41,667
Warrants exercisable (in Shares)							2,500,000
Refinanced loan percentage			93.60%
Loan repaid date	Oct. 19, 2021	May 7, 2021	Apr. 27, 2021
Loan balance								$ 412,560
Note payable		$ 225,000
Debt discount associated							$ 1,444,542
Fair value of warrants							928,779
Beneficial conversion feature							515,763	250,000
Loan agreement	$ 300,000
Accrued interest	91.23%
Maturity date	May 27, 2021
Debt instrument description				convertible note has a face value of $250,000, matures August 1, 2022, and accrues interest at 8% per annum.
Conversion price (in Dollars per share)				$ 0.1
Maturity date	May 27, 2021
Private Placement [Member]
Debt (Details) [Line Items]
Aggregate units (in Shares)					1,900	3,000
Subscription Agreement [Member]
Debt (Details) [Line Items]
Loan agreement				$ 250,000
Interest per annum				8.00%	12.00%	12.00%
Convertible into shares (in Shares)				2,500,000
Conversion price per share (in Dollars per share)				$ 0.1
Net carrying amount							177,083	52,083
Convertible notes							250,000	250,000
Unamortized debt discount							$ 72,917	$ 197,917
Warrants exercisable (in Shares)							2,500,000
Common stock price per share (in Dollars per share)					$ 0.2	$ 0.2	$ 0.25
Aggregate units (in Shares)						3,000
Principal amount					$ 1,000	$ 1,000
Warrant for purchase shares (in Shares)					5,000	5,000
Common stock exercise price per share (in Dollars per share)					$ 0.4	$ 0.4
Aggregate net proceeds					$ 3,000,000	$ 3,000,000
Convertible term description						The Initial Convertible Term Notes and the Initial Warrants mature on March 31, 2022 and March 31, 2023, respectively, and accrued interest at a rate of 12% per annum payable on a quarterly basis.
Loan Agreement [Member]
Debt (Details) [Line Items]
Loan agreement										$ 600,000
Interest per annum										84.00%
Debt [Member]
Debt (Details) [Line Items]
Net carrying amount							$ 177,083
Convertible notes							250,000
Unamortized debt discount							$ 72,917
Convertible Debt [Member]
Debt (Details) [Line Items]
Conversion price per share (in Dollars per share)					$ 0.2	$ 0.2
Aggregate units (in Shares)					1,900
Principal amount					$ 1,000	$ 1,000
Warrant for purchase shares (in Shares)					5,000	5,000
Common stock exercise price per share (in Dollars per share)					$ 0.4	$ 0.4
Aggregate net proceeds					$ 1,900,000	$ 1,900,000
Convertible term description					The Convertible Term Notes and Warrants mature on September 30, 2022 and April 30, 2023, respectively, and accrued interest at a rate of 12% per annum payable on a quarterly basis.

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	Oct. 22, 2021	Aug. 19, 2021	Feb. 25, 2020	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 15, 2021	Jun. 30, 2021
Related Party Transactions (Details) [Line Items]
Shares issued (in Shares)				200,000	5,000,000	3,500,000
Notes payable, related party					$ 0	$ 458,599
Promissory note received				$ 281,771	$ 281,771
Loan agreement		$ 237,590
Note interest	14.00%
Common shares and warrants issued (in Shares)				199,143,664	196,949,801	97,005,817	250,000
Exchange amount							$ 50,000
Interest rate	14.00%
Common shares and warrants (in Shares)					73,950,000		250,000
Trichome Capital Inc [Member]
Related Party Transactions (Details) [Line Items]
Exchange amount							$ 152,000
Common shares and warrants (in Shares)							760,000
Restricted Stock Units [Member]
Related Party Transactions (Details) [Line Items]
Vested shares (in Shares)			200,000
Converted into common shares (in Shares)			200,000
CMI Transaction [Member]
Related Party Transactions (Details) [Line Items]
Shares issued (in Shares)								2,500,000

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	1 Months Ended							3 Months Ended							12 Months Ended
	Jan. 31, 2022	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Feb. 29, 2020	Jul. 31, 2019	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Aug. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 15, 2021
Shareholders' Equity (Details) [Line Items]
issuance costs (in Dollars)											$ 72,096
Issuance of common stock shares																	790,000
Professional fees (in Dollars)																	$ 395,000
Issuance of common stock shares												10,000,000
Transaction shares												6,903,172
Agreements shares												2,500,000
Share exchange for services												633,125
Common stock shares	1,000,000							458,334	50,700,000	798,414
Raising capital										633,707
Interest rate										92,127
Common stock in exchange for services								550,000	1,570,501
Common stock in exchange for extinguishment of debt.								185,529	24,621,119
Fair value of RSU’s vested (in Dollars)								$ 848,600					$ 146,602		$ 2,851,102	$ 309,790
Unrecognized stock-based compensation (in Dollars)								$ 187,761					$ 472,087		78,676	600,241
Stock-based compensation expense (in Dollars)															$ 968,205	$ 555,532
Shares issued								200,000	5,000,000					3,500,000	5,000,000	3,500,000
Total fair value (in Dollars)															$ 968,205	$ 555,532
Warrants shares									73,950,000						73,950,000			250,000
Exercise price (in Dollars per share)															$ 0.4
Additional paid in capital (in Dollars)								$ 42,215,245	$ 41,916,207					$ 19,138,947	$ 41,916,207	$ 19,138,947
Fair value of additional paid in capital (in Dollars)									$ 1,867,960						$ 1,867,960
Common Stock [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares											14,325,005
Gross proceeds (in Dollars)											$ 7,162,503
Price per share (in Dollars per share)											$ 0.5
Issuance of common stock shares							13,553,233								10,000,000
Shares issued								291,667
Warrants [Member]
Shareholders' Equity (Details) [Line Items]
Shares issued									2,500,000					4,525,898	2,500,000	4,525,898
Exercise price (in Dollars per share)															$ 0.25	$ 0.3
Additional paid in capital (in Dollars)									$ 266,383						$ 266,383
March 31, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															15,000,000
April 30, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															9,500,000
September 17, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															1,000,000
October 15, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															7,750,000
October 26, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															9,510,000
November 2, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															190,000
November 10, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															27,060,000
November 15, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															1,940,000
November 17, 2023 [Member]
Shareholders' Equity (Details) [Line Items]
Warrants expire															750,000
Employees [Member]
Shareholders' Equity (Details) [Line Items]
Stock-based compensation consisted of equity awards granted and vested (in Dollars)															$ 1,272,779
Stock Option Awards [Member]
Shareholders' Equity (Details) [Line Items]
Additional paid in capital (in Dollars)									$ 1,867,960						1,867,960
Executive [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares					1,175,549	400,000
Board [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares		757,895				200,000
Shareholders [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares				15,050,000
Shares of common stock cancelled				15,050,000
Employees [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares			10,000
Stock-based compensation consisted of equity awards granted and vested (in Dollars)								$ 27,179
Shareholder One [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares			300,000
Shares of common stock cancelled			300,000
Raise capital [Member]
Shareholders' Equity (Details) [Line Items]
Issuance of common stock shares		60,000											1,491,819	3,535,665
RSU’s [Member]
Shareholders' Equity (Details) [Line Items]
Stock-based compensation expense (in Dollars)								140,815					$ 250,817		1,685,066	$ 734,752
Director [Member]
Shareholders' Equity (Details) [Line Items]
Stock-based compensation consisted of equity awards granted and vested (in Dollars)								108,771							347,275
Consultants [Member]
Shareholders' Equity (Details) [Line Items]
Stock-based compensation consisted of equity awards granted and vested (in Dollars)								$ 4,866							$ 65,012

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Schedule of the company's RSU award activity - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of the company's RSU award activity [Abstract]
Restricted Stock Units, Outstanding beginning balance	2,200,003	2,453,175
Weighted Average Grant Date Fair Value, Outstanding beginning balance	$ 0.45	$ 0.45
Restricted Stock Units, Granted	1,469,511	6,650,000
Weighted Average Grant Date Fair Value, Granted	$ 0.27	$ 0.15
Restricted Stock Units, Vested	(1,735,529)	(6,903,172)
Weighted Average Grant Date Fair Value, Vested	$ 0.49	$ 0.15
Restricted Stock Units, Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Restricted Stock Units, Outstanding ending balance	1,933,982	2,200,003
Weighted Average Grant Date Fair Value, Outstanding ending balance	$ 0.27	$ 0.45

Shareholders' Equity (Details_2

Shareholders' Equity (Details) - Schedule of stock options activity - Stock Option [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Shareholders' Equity (Details) - Schedule of stock options activity [Line Items]
Stock Option Shares, Outstanding, beginning	8,500,000	3,500,000
Weighted Average Exercise Price, Outstanding, beginning	$ 0.18	$ 0.16
Weighted Average Remaining Contractual Term, Outstanding, beginning	9 years 2 months 12 days	8 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding, beginning	$ 1,579,108	$ 581,591
Stock Option Shares, Granted and vested		5,000,000
Weighted Average Exercise Price, Granted and vested		$ 0.2
Weighted Average Remaining Contractual Term, Granted and vested		9 years 6 months
Aggregate Intrinsic Value, Granted and vested		$ 987,517
Stock Option Shares, Forfeited
Weighted Average Exercise Price, Forfeited
Weighted Average Remaining Contractual Term, Forfeited
Aggregate Intrinsic Value, Forfeited
Stock Option Shares, Outstanding, ending	8,500,000	8,500,000
Weighted Average Exercise Price, Outstanding, ending	$ 0.18	$ 0.18
Weighted Average Remaining Contractual Term, Outstanding, ending	9 years	9 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, ending	$ 1,579,108	$ 1,579,108

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory federal income tax rate		21.00%	21.00%
Net operating loss carryforwards		$ 10,194,806	$ 2,004,266
State net operating losses		16,641,692	8,042,840
NOLs with no expiration		9,988,297
Net operating losses		2,749,613	715,079
Valuation allowance		$ 3,269,776	$ 1,031,792
Annual effective tax rate	0.00%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of provision (benefit) for income taxes - Income Taxes [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current (benefit) provision
Federal
State
Total Current
Deferred (benefit) provision
Federal	3,724	3,724
State	6,511	6,511
Total Deferred	10,235	10,235
Total Provision	$ 10,235	$ 10,235

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of statutory federal income tax rate - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of statutory federal income tax rate [Abstract]
Income Taxes At Statutory Federal Income Tax Rate, Tax	$ (2,202,256)	$ (2,517,221)
Income Taxes At Statutory Federal Income Tax Rate, Percentage	21.00%	21.00%
State Taxes, Net Of Federal Income Tax Benefit, Tax	$ 6,511	$ 6,511
State Taxes, Net Of Federal Income Tax Benefit, Percentage	(0.06%)	(0.05%)
Meals & Entertainment, Tax		$ 261
Meals & Entertainment, Percentage	0.00%	0.00%
Penalties and Fines, Tax
Penalties and Fines, Percentage	0.00%	0.00%
Return to Provision Adjustment - Permanent Items, Tax
Return to Provision Adjustment - Permanent Items, Percentage	0.00%	0.00%
Deferred Only Adjustment, Tax		$ (228,539)
Deferred Only Adjustment, Percentage	0.00%	1.91%
Change in Valuation Allowance, Tax	$ 1,838,803	$ 200,791
Change in Valuation Allowance, Percentage	(17.53%)	(1.68%)
Section 280E Expense Disallowance	$ 367,177	$ 2,548,431
Section 280E Expense Disallowance, Percentage	(3.50%)	(21.26%)
Other, Tax
Other, Percentage	0.00%	0.00%
Effective tax, Tax	$ 10,235	$ 10,235
Effective tax, Percentage	(0.10%)	(0.09%)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of deferred tax assets and liabilities [Abstract]
Stock Compensation	$ (7,335)	$ 62,606
Stock Compensation - Options	259,057
Accrued Salary	44,384
Trademark/Trade Name	(8,033)	(4,765)
Developed Manufacturing Process - Extraction	(53,747)	(31,884)
Customer Relationships	1,947	1,158
Patent	3,589
In-Process Research & Development - CryoCann	(26,376)
Goodwill - CMI	179,892	168,688
In-Process Research & Development - CMI	98,135	105,985
Goodwill - CryoCann	3,490
NOL - Federal Pre-2018	43,367	43,367
NOL - Federal Post-2017	2,097,542	377,529
NOL - State	608,703	294,183
Deferred Tax Assets (Liabilities)	3,244,615	1,016,867
Valuation Allowance	(3,269,776)	(1,031,792)
Net Deferred Tax Assets (Liabilities)	$ (25,160)	$ (14,926)

Commitments & Contingencies (De

Commitments & Contingencies (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Commitments & Contingencies (Details) [Line Items]
Other lease term	12 months		12 months
Other lease payments	$ 0	$ 14,392	$ 59,051	$ 73,777
Present value of liabilities	0	132,230	519,671	472,154
Operating lease cost	0	$ 1,595,254	664,686	$ 627,132
CMI Transaction [Member]
Commitments & Contingencies (Details) [Line Items]
Assets recognized upon transaction	$ 1,411,461		$ 1,411,461

Subsequent Events (Details)

Subsequent Events (Details)	Apr. 05, 2022shares	Jan. 12, 2022$ / sharesshares	Jan. 10, 2022$ / shares	Mar. 31, 2022USD ($)$ / sharesshares	Dec. 31, 2021USD ($)shares	Aug. 31, 2021$ / shares	Dec. 31, 2020shares
Subsequent Events (Details) [Line Items]
Effect a reverse stock split, description			not less than three (3) shares and not more than ten (10) shares, into one share of Common Stock
Shares issued				200,000	5,000,000		3,500,000
Number of directors				3
Common stock issued				1,091,667
Price per share (in Dollars per share) | $ / shares				$ 0.25
Number of executive officer				1
Property and equipment (in Dollars) | $				$ 115,945
Shares granted				1,469,511	6,650,000
Common Stock [Member]
Subsequent Events (Details) [Line Items]
Shares issued				291,667
Stock price (in Dollars per share) | $ / shares						$ 0.5
Price per share (in Dollars per share) | $ / shares				$ 0.35
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Common Stock, par value (in Dollars per share) | $ / shares			$ 0.001
Number of executive officers		3
Number of directors		2
Stock price (in Dollars per share) | $ / shares		$ 0.27
Shares granted	500,000
Vested date	Jan. 1, 2023
CMI [Member]
Subsequent Events (Details) [Line Items]
Loan amount (in Dollars) | $					$ 620,000
Three Executive Officers [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Shares issued		735,529
Two Directors [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Shares issued		371,058
Three Directors [Member]
Subsequent Events (Details) [Line Items]
Shares issued				800,000
One Executive Officer [Member]
Subsequent Events (Details) [Line Items]
Price per share (in Dollars per share) | $ / shares				$ 0.28

Variable Interest Entity (Det_4

Variable Interest Entity (Details) - Schedule of CMI statement of operations - VIE's [Member] - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity (Details) - Schedule of CMI statement of operations [Line Items]
Net sales		$ 1,695,925	$ 5,891,894	$ 6,860,282
Cost of goods sold, inclusive of depreciation		1,118,735	4,132,696	4,901,237
Gross profit		577,190	1,759,198	1,959,045
Operating expenses
Personnel costs		154,460	428,728	402,389
Sales and marketing		226,347	816,683	908,502
General and administrative		28,988	112,934	231,376
Legal and professional fees		21,515	44,092	156,782
Total operating expenses		431,310	1,402,437	1,725,950
Gain from operations		145,880	356,761	233,095
Other income / (expense)
Interest expense		(29,264)	(49,803)	(153,592)
Total other income / (expense)		(29,264)	(49,803)	(5,178,324)
Net loss		$ 116,616	$ (2,725,001)	$ (4,955,464)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Computer equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	3 years	3 years
Computer equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Furniture and fixtures [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Furniture and fixtures [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	7 years	7 years
Machinery and equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Machinery and equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	8 years	8 years
Leasehold improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful life of property and equipment [Line Items]
Property, plant and equipment, useful life	15 years	15 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of intangible assets	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of estimated useful lives of intangible assets [Abstract]
Patent	10 years	10 years
In process research and development	Indefinite	Indefinite

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of amounts relate to discontinued operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenues		$ 1,130,504		$ 781,455
Medical retail [Member]
Disaggregation of Revenue [Line Items]
Total revenues		1,130,504		11,200
Medical wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenues		556,310		700
Recreational wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenues		$ 9,010		$ 769,555

Business Combination (Details_4

Business Combination (Details) - Schedule of purchase price - Cryocann Acquisition [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Business Combination (Details) - Schedule of purchase price [Line Items]
Cash	$ 2,247,684	$ 2,247,684
Common stock	1,804,500	1,804,500
Promissory Note	1,220,079
Total purchase price	$ 5,272,263	$ 5,272,263

Business Combination (Details_5

Business Combination (Details) - Schedule of business combination - Cryocann Acquisition [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible assets:
In process research and development, Fair Value	$ 3,209,000	$ 3,209,000
In process research and development, Weighted average useful life (in years)	Indefinite	Indefinite
Patent, Fair Value	$ 873,263	$ 873,263
Patent, Weighted average useful life (in years)	10 years	10 years
Goodwill, Fair Value	$ 1,190,000	$ 1,190,000
Total assets acquired, Fair Value	$ 5,272,263	$ 5,272,263

Discontinued Operations (Deta_4

Discontinued Operations (Details) - Schedule of CMI discontinued operations - CMI Transaction [Member] - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Discontinued Operations (Details) - Schedule of CMI discontinued operations [Line Items]
Net sales		$ 1,695,925	$ 5,891,894	$ 6,860,282
Cost of goods sold, inclusive of depreciation		1,118,735	4,132,696	4,901,237
Gross profit		577,190	1,759,198	1,959,045
Operating expenses:
Personnel costs		154,460	428,728	402,389
Sales and marketing		226,347	816,683	908,502
General and administrative		28,988	112,934	231,376
Legal and professional fees		21,515	44,092	156,782
Total operating expenses		431,310	1,402,437	1,725,950
Gain / (loss) from operations		145,880	356,761	233,095
Other income (expenses):
Interest expense		(29,264)	(49,803)	(153,592)
Total other expenses		(29,264)	(49,803)	(5,178,324)
Net gain / (loss) from discontinued operations, before taxes		116,616	(2,714,766)	(4,945,229)
Income taxes			(10,235)	(10,235)
Net gain / (loss) from discontinued operations		$ 116,616	$ (2,725,001)	$ (4,955,464)

Property and Equipment, Net (_3

Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 233,641	$ 225,000	$ 4,107,596
Less: Accumulated depreciation			(1,392,825)
Property and equipment, net	233,641	225,000	2,714,771
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross			2,770,385
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	233,641	225,000	1,065,885
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross			43,331
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross			$ 227,995

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details) - Schedule of identifiable intangible assets - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Indefinite-lived
Indefinite-lived Intangible assets, Gross Amount	$ 4,082,263	$ 4,082,263	$ 4,082,263
Indefinite-lived Intangible assets, Accumulated Amortization	(65,495)	(43,663)	(43,663)
Indefinite-lived intangible assets, Carrying Value	$ 4,016,768	$ 4,038,600	$ 4,038,600
Patent [Member]
Amortized
Amortized intangible assets, Estimated Useful Life (Years)	10 years	10 years	10 years
Amortized intangible assets, Gross Amount	$ 873,263	$ 873,263	$ 873,263
Amortized intangible assets, Accumulated Amortization	(65,495)	(43,663)	(43,663)
Amortized intangible assets, Carrying Value	$ 807,768	$ 829,600	$ 829,600
In-process research and development [Member]
Indefinite-lived
Indefinite-lived intangible assets, Estimated Useful Life (Years)	Indefinite	Indefinite	Indefinite
Indefinite-lived Intangible assets, Gross Amount	$ 3,209,000	$ 3,209,000	$ 3,209,000
Indefinite-lived Intangible assets, Accumulated Amortization
Indefinite-lived intangible assets, Carrying Value	$ 3,209,000	$ 3,209,000	$ 3,209,000

Shareholders' Equity (Details_3

Shareholders' Equity (Details) - Schedule of the company's RSU award activity - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of the company's RSU award activity [Abstract]
Restricted Stock Units, Outstanding beginning balance	2,200,003	2,453,175
Weighted Average Grant Date Fair Value, Outstanding beginning balance	$ 0.45	$ 0.45
Restricted Stock Units, Granted	1,469,511	6,650,000
Weighted Average Grant Date Fair Value, Granted	$ 0.27	$ 0.15
Restricted Stock Units, Vested	(1,735,529)	(6,903,172)
Weighted Average Grant Date Fair Value, Vested	$ 0.49	$ 0.15
Restricted Stock Units, Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Restricted Stock Units, Outstanding ending balance	1,933,982	2,200,003
Weighted Average Grant Date Fair Value, Outstanding ending balance	$ 0.27	$ 0.45

Shareholders' Equity (Details_4

Shareholders' Equity (Details) - Schedule of stock options activity - Stock Option [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Shareholders' Equity (Details) - Schedule of stock options activity [Line Items]
Stock Option Shares, Outstanding, beginning	8,500,000	3,500,000
Weighted Average Exercise Price, Outstanding, beginning	$ 0.18	$ 0.16
Weighted Average Remaining Contractual Term, Outstanding, beginning	9 years 2 months 12 days	8 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding, beginning	$ 1,579,108	$ 581,591
Stock Option Shares, Granted and vested		5,000,000
Weighted Average Exercise Price, Granted and vested		$ 0.2
Weighted Average Remaining Contractual Term, Granted and vested		9 years 6 months
Aggregate Intrinsic Value, Granted and vested		$ 987,517
Stock Option Shares, Forfeited
Weighted Average Exercise Price, Forfeited
Weighted Average Remaining Contractual Term, Forfeited
Aggregate Intrinsic Value, Forfeited
Stock Option Shares, Outstanding, ending	8,500,000	8,500,000
Weighted Average Exercise Price, Outstanding, ending	$ 0.18	$ 0.18
Weighted Average Remaining Contractual Term, Outstanding, ending	9 years	9 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, ending	$ 1,579,108	$ 1,579,108